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Sommaire
Objectifs: Une méta-analysc comparant la validité des dosages sériques de Procalcitonine
(PCÏ) et de Protéine-C réactive (CRP) pour diagnostiquer une infection d’origine
bactérienne chez les patients hopitalisés.
Méthodes: Une recherche de la littérature de 1970 à 2002 permet d’identifier les articles
évaluant la PCT et la CRP lors d’infections bactériennes. Les études sont revues P trois
experts indépendants et les données sont extraites dans des tables de contingences. Les
auteurs des articles sont contactés po’ir vérifier les données.
Résultats: 351 titres sont identifiés, 110 études prospectives faites chez des Patients
hospitalisés sont évaluées et 12 articles sont inclus (1497 patietits). Les données sont
synthétisées en utilisant des méthodes de régressions linéaires et des courbes SROC
(Summary Receiver Operating Characteristic sont générées. La valeur Q, qui réflète la
validité du test (correspond au point d’intersection de la courbe SROC avec la ligne où la
sensibilité et la spécificité sont égales) est calculée. Pour différencier entre les infections
bactériennes et les inflammations non-infectieuses, la PCT est plus sensible que la CRP
(0,8$ liC 95% 0,80-0,93] versus 0,75[IC 95% 0,62-0,841). La PCT est aussi plus
spécifique (0,81 liC 95% 0,67-0,90] versus 0,67 IC 95% 0,56-0,77]). La valeur Q est
meilleure pour la PCT que pour la CRP (0,82 versus 0,73). Pour différencier entre les
infections d’origine bactériennes et virales, la PCT est plus sensible que la CRP (0,92 IC
95% 0,86-0,95] versus (],$6 ETC 95% 0,65-0,95]). Les spécificités sont semblables (0,73
lC 95% 0,42-t),91] versus 0,70 ETC 95% 0,19-t),96]). La valeur Q de la PCT est meilleure
que pour la CRP (0,89 versus 0,83).
Conclusion: La validité de la PCT est plus élevée que celle de la CRP et ce test devrait
être favorisé en clinique chez les patients hopitalisés.
‘1ots—clés: méta-analysc, revue systématique, infections bactériennes, inflammation,
sepsis, tests diagnostiques, otéine C-réactive, procalcitonine
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Summary
Objective: Meta-analysis comparing the accuracv of serum Procalcitomn (PCT) and C
reactive protein (CRP) for the diagnosis of bacterial infection in hospitalized patients.
Methods: A literature search between 1970 and 2002 for identifving articles evaluating
PCT and CRP for the diagnosis of bacterial infections vas performed. Each article vas
independendy reviewed by three revÏewers and data extracted in 2x2 tables. Authors of
articles were contacted to verify data.
Resuits: 351 tides were identifled; 110 prospective studies among hospitalized patients
were evaluated and 12 articles (1497 patients) were included. Data were summarized
using linear regression methods and summary receiver operaung charactenstic curves
(SROC) were generated. Q values, which reflect accuracy of the test and correspond to
the intersection point of the SROC curve with the lime where sensidvity and specificity
are equal, were calculated. PCT was more sensitive than CRP: 0.8$ [95% CI 0.80 — 0.93]
versus 0.75 [95% CI 0.62 — 0.84] to differentiate becween bacterial and non-infective
causes of inflammation. PCT was also more specific: 0.81 [95% CI 0.67 — 0.90] versus
0.67 [95% CI 0.56-0.77]. The Q value for PCT was bigher than for CRP: 0.82 and 0.73
respectively. The sensitivity to differentiate between bacterial and viral infections xvas
higher for PCT than for CPY (0.92 [95% CI 0.86 — 0.95] versus 0.86 [95% CI 0.65 —
0.95]). Th specificities were comparable (0.73 [95% CI 0.42 — 0.91] versus 0.70 [95% CI
0.19 — 0.96]). The Q value was higher for PCT: 0.89 versus 0.83.
Conclusion: The overail accuracy of PCT is higher than that of CRP and should be
favored for use in cinical practice in hospitalized patients.
Key words: meta-analysis, systematic review, bacterial infections, inflammation, sepsis,
diagnostic tests, C-reactive protein, procalcitonin
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Introduction
Dc/ùïitioizs o/SIRS u;zcÏ scbsis
In 1992, the American College of Cliest Physicians/Society of Critical Care IViedicine
ACCP/SCCVD Consensus Conference arrived at die current definition of SIRS, sepsis,
severe sepsis, septic shock and multiple organ dysfunction syndrome.’
Systemic inflammatory response syndrome (SIRS) encompasses die features of systemic
inflammation without end-organ damage, identifiable bacteremia, and the need for
pharmacological support. The hallmark of SIRS is a proinftarnmatory state that is rnarked
by tachycarclia, tachypnca or hyperpnea, leukocytosis or leukopenia, pyrexia or
hypothermia. The key transition from SIRS to sepsis is the presence of an identified
pathogen as die cause for SIRS. Most often a bacterial infection xviii cause a systemic
mflairimatory response, which can be then characterized as sepsis.
ln sepsis, most often bacterial, regulation of die eariy response to infection may be lost,
and a massive cletrimental systernic reaction occurs. As result, progressive tissue damage
and organ cÏysfunction may occur. Severe sepsis is the preseice of sepsis (SIRS caused by
an infection) associateci with organ dysfunction, hypoperfusion, or hypotension that
usually responds to adequate fluid resuscitation. There is a subset ofpeopie with severe
sepsis \vho develop hypotension despite adequate fluid resuscitation and require inotropic
or vasopressor agents; these patients have septic shock. Multiple organ dysfunction
syndrome (MODS) is defined as the presence of at least two altered organ function in a
patient who is acutely iII ancl in whom homeostasis cannot be maintained without
intervention.
Epiderniotogy ofsepsis
Sepsis is a major challenge in medicine. Sepsis is extremely common, lias a very high
morbidity and mortality and consumes considerable health-care resources. Around
700,000 cases of sepsis are reported annually worldwide and accounting for about $15
billion in health care costs in the U.S. alone.2 It is the second leading cause of death
among patients in non-coronary intensive care units and the 10 leading cause of death
overail in the United States.3 Sepsis is often lethal, killing 20 a 50% of severely affected
patients.1 Bacterial infections are the major cause of sepsis
Martin et al.3 recendy reviewed the epidemiology of sepsis by assessing discharged data on
approximately 750 million hospitalizations in ±e U.S. over the 22-year penod from 1979
through 2000. During this period, there were 10,319,418 reported cases of sepsis,
accounting for 1.3 % of ail hospitalizadons. Even after normalizing for the population
census, there was a yearly mcrease of 8.7 % in the incidence of sepsis, going from about
$2.7 cases per 100,000 population to nearly 240.4 per 100,000 population. The average
age of patients with sepsis increased consistendy over urne, from 57.4 years in the flrst 5-
year subperiod (1979 through 1984) to 60.8 years in the last 5-year subpenod (1995
through 2000). Wbites had the lowest fates of sepsis dunng the swdy period, with both
blacks and other nonwhite groups having a similarly elevated nsk as compared with
whites. Black men had the highest fate of sepsis, the youngest age of onset, and the
bighest mortality. When considering causative organisms, gram-negauve bacteria remain
as aiways, the most important cause of sepsis. The greatest relative changes, however,
were observed in die incidence of fungal infections, which increased by 2O7%. Gram-
positive bacteria became the predominant pathogen after 1987; there was an average
increase by 26.3% per year in the incidence of gram-positive sepsis. The total in-hospital
mortality rate feil from 27.8% during the initial 5-year subpenod (1979 through 1984) to
17.9% during the last 5-year subpenod (1995 through 2000). Yet, because of the
increased incidence of sepsis, the total number of deaths continues to increase. Over
time, admission days significandy decreased. However, the rate of discharge of survMng
3patients to other heath care facifities (i.e., rehabifitation centers or other long-term care
facifities) almost doubled, going from 16.$% to 31.8%.
Severe sepsis is also a significant health problem in children. Watson et al.5 swdied the
epidemiology of severe sepsis in children using 1995 hospital discharge and population
data from seven states (24% of the United States population). They found an incidence
of 0.56 cases per 1,000 population per year. The incidence was the highest in infants
(5.16 per 1,000) and feil dramatically in older children (0.20 per 1,000 in 10 to 14 years
old). h was 15% higher in boys than in girls (0.60 versus 0.52 per 1,000). Hospital
mortallty was 10.3% (6.2 per 100,000 population). Haif of the cases had underlying
disease (49.O%), and over one-flfth (22.9%) were low-birth-weight newborns.
Respiratory infections (37%) and primary bacteremia (25%) were die most common
infections. The mean length of stay and cost were 31 days and $40,600, respectively.
Esdmated annual total costs were 1.97 billion U.S. dollars nationally.
Severe sepsis is especially common in the elderly and is hkely to increase substantially in
the coming years as the world population ages.2 Massive resources have been invested in
early diagnosis of sepsis, in developing and evaluating potential therapies, and
considerable effort has been undertaken to understand the systemic inflammation and
multiple-system organ failure characteristics of severe sepsis.
4Diagnosis ofSpsis
Early specific treatrnent for sepsis is beneficial in trying to prevent the evolution to the
more severe forms of the disease, such as severe sepsis, septic shock and MODS.
However, treating everv SIRS with antibiotics is hazardous. It is estirnated that more
than 60% of the ICU patients are treated with broad-spectrum antibiotics at an urne of
their stay. Antibiotics given to a non-infected patient increases the risk of acquiring
nosocomial infections caused by multiresistant organisms6’7 and cari double the risk of
death.811 Avoiding the use ofunnecessary antibiotic use and opurnizing the
administration of antimicrobial agents help to irnprove patient outcome, while
minimizing resistance.12 In an European ICU, when a restrictive strategy for the use of
antibiotics was adopted, a decrease of 22% in the expenses for antibioucs (saving of
14,400 Euros/year) was noted.13
Unfortunately cinical symptoms of sepsis are usually subtie ami non-specific and the
problem remains the diagnosis of underlying bactenal infection. Presently, diagnosis by
using bactenal culture methods remains the standard. However, there is an unavoidable
delay in obtaining die resuits (usually at least 24-4$ hours). Besides, only less than one
haif of the patients with signs ami symptoms of sepsis have positive resufts on blood
culture.14 The demonstration of bacteria in sterile sites is not always evident. Clinically,
bacterial infection cari be evidenced by finding a collection of purulent material.
Significant amount of bacteria cari also be recognized by Gram’s stain. Rapid
immunological detection methods for the identification of bacterial components are
available for some pathogens. Hence the identification of suitable markers for the early
diagnosis of bacterial infections is paramount.
Presently two markers, procalcitonin (PCT) and C-reacuve protein (CRP), are being
widely swdied to investigate their clinical utility vis-à-vis the diagnosis of bacterial
infections.
5Procaïttonin
Procalcitonrn was described as a precursor for calcitonin in 1975, but it was flot until
1992 that it was suggested to be an inflammatory mediator, rising in burned patients.16 A
close correladon between bacterial infections and serum PCT levels was reported in
1993J7 Thereafter, several studies correlated PCT levels with bacterial infections.
Procalcitonin (PCT) is a 116 amino-acid (13 kDa) protein, derived from the
preprocalcitonin. PCT concentrations in the plasma of healthy subjects are negligible,
usuafly within the picogram per miiiiliter range (10-50 pg/mL).18 PCT is the pre
hormone of calcitonin and is a member of the “CAPA protein family” (c’alcitonin gene
related peptide-mylin-(pro)-calcitonin-adrenomeduliin family). PCT mRNA is
synthesized by the CÀLC-I gene on chromosome 11 during normal conditions, sepsis
and inflammation. In voluntary healthy subjects, PCT is produced by the C ceils of the
thyroid, where it is processed into calcitonin and stored in secretory granules. Calcitonin
is then released from these granules in response to hormonal or metabolic stimuli. No
other genes are known to produce inflammation-induced PCT. The gene is present in
various mammals and other species (e.g. salmon), but the DNA sequences and amino
acids found in these animals are species-dependent. The large degree of conservation of
the gene in vanous species indicates that it may have biologically important functions,18
stiil to be established.
Two types ofPCT ruRNA are synthesized witbin PCT-producing ceils, resulting in two
different proteins, PCT-I and PCT-II. They are very similar in structure, differencing
only at eight C-terminal amino acids.18 The type of protein synthesized or processed
depends on die individual clrcumstances, the type of ceils involved, the stimulus for
cellular activation, and individual suscepdbffity ofvarious ceil types to these stimuli.
Variable quantities ofPCT-I and PCT-II ruRNA can be detected in different tissues.
They are both detected by die commercially available assay.’8
6aminoproCT calcitonin CCP
LUMItest PCT
Figure I — Cartoon PCT molecule and antibody site binding of the commercia.lly available
assay (LUMItest PCI)
aminoproCT, aminoprocalcitonin; CCP, calcitonin carboxyterminal pepude
The stimulus for PCT production during bacterial infection is stifi under investigation.
Some flndings suggest that the release ofproximal cytokines in sepsis can initiate a greater
increase in PCT. I-ligh serum PCT concentrations are measured during septic shock and
respiratory distress, where inassive amounts of TNF are released. The injection of TNF
ci. into healthy animais is associated with an elevation of serurn PCT levels.19 The
mtravenous injection of endotoxin into healthy volunteers causes the rapid synthesis of
PCT.2° Increased PCT concentrations were demonstrated after treatment with human
recombinant TNf-Œ and IL-6 in cancer patients.21
The site of PCT production during severe generalized infection is stili uncertain and
controversial. Elevated serum concentrations ofPCT were found in patients with sepsis
who have undergone prior total thyroidectomy;17 thus, high PCT plasma levels during
systemic inflammation and sepsis are unlikely to be of thyroidal origin. Human
penpheral mononuclear ceils are another source for PCT production dunng inflammation
and sepsis.n However, sigmflcant quantities ofPCT were induced dunng leukopenia in
a patient on immunosuppressants for chemotherapy, while no leukocytes were detectable
in visuafly and automatically analyzed blood smears.24 The liver might be a more
important source of PCT during inflammation and bacterial infection, as demonstrated by
increased PCT production in liver slices after stimulation with recombinant human TNF
ci. or IL-6.21
7On the other hand, PCT might have an active functional protective role in patients with
sepsis. In vitro experiments showed that PCT has influence on cytokine expression.
TNf-cL induction vas significandy reduced in the presence of PCT or its C-terminal 57
amino acid fragment.25 In culwred smooth muscle ceils, low or moderatelv elevated PCT
concentrations signiflcantly suppressed TNF-Œ and IfN-y-stimulated production of
cDNA of iNOS.26 However, in animal model of sepsis, increased mortalitv vas obsenred
following intravenous PCT injections. Moreover, neutralization ofPCT with antisemm
improved the survival of animais foflowing Escherichia cou inoculation.27
Although stili uriner investigation, it is beieved that there is protein modification of the
PCT molecule, which most likely occurs by glycosylation or deamination. Two N-
terminal amino acids (Ala-Pro) are removed by the enzyme dipedtidyl peptidase IV (DP
IV) or CD26. The DP IV enzyme is located on renal, epithelial and endotheiai ceils, and
is induced by proinflammatory mediators and endotoxin. Akhough the turnover rate of
DP IV cleavage is low due to the length of the PCT molecule, a molar excess of the
enzyme is prescrit in vivo, resuffing in high concentrations of tmncated PCI in the plasma
of patients with severe sepsis. Furthermore, DP IV is known to modifv other proteins in
which the active form is converted to an inactive form, e.g., chemokines like granulocyte
chemotacuc protein-2, macrophage-derived chemokine, etc.
The exact funcuon of biologically active PCT is flot known; it is possible that it
participates in amplifying die inflammatory response during infection. Recombinant
procalcitonin and various synthetic proteins have been invesdgated in vitro and in
experimental studies. When PCT was applied simultaneously with the inflammatory
stimuli TNf-Œ/IfN-y, PCT inhibited synthesis of the inflamrnatory mediator nitric oxide
(NO) in vascular smooth muscle culture.26 However, the lime course of PCT during
sepsis suggests that it is not a proximal event in the inflamrriatory cascade, so that PCT is
not prescrit imually with TNF-Œ and IFN-y in the early stages of inflammation. After die
injection of bacterial products in vivo, it was found that PCT concentrations increased
from the hour onward, reaching a plateau after 6 hours, whereas TNF-Œ peaks were
detected earlier.2° Thus, it was invesugated whether PCT affects NO synthase (iNOS) by
8LPS, TNf-a, and IFN-y, taking into account the typical 3-hr delay of PCT increase
foflowing a bacterial challenge. A further stimulation of inducible nitric oxide synthase
transcription rate vas found, suggesting that PCT acts as a modulator that augments the
inftammatory response triggered by agonists like lipopolvsaccharide, tumor necrosis
factor-u, and interferon-y.28
There are some studies that show that PCT concentrations are much higher in patients
with severe sepsis than in ±ose with sepsis alone.29’ 3u PCT may have a hazardous effect;
in vivo experiments in hamster endotoxin shock models showed that PCT administered to
septic animais increased mortality and that PCT antiserum protected the animaIs from the
lethal effects of sepsis.27 In the baboon sepsis model, PCT concentrations were
signiflcandy different between survivors and nonsurvivors.31 PCT concentration also
seems to correlate with the severity of organ dysfunction, as deflned by different scoring
systems, such as SOFA (sepsis-related organ failure assessment),32 or APACHE II (acute
physiology and chromc health evaluation II) or survival3335 and poorer prognosis.36’37
Although initially high PCT concentrations do not necessarily indicate a poor prognosis,
serum PCT, could potentiallv be used to monitor disease actlv tv in patients with sepsis,
severe sepsis and septic shock.
9C-Reactive Protein
CRP was one of the flrst “acute phase” markers described. It vas originaily isolated in
1930 in the serum of patients with pneumonia. With its bigh afflnity for the
pneumococcal C polvsaccharide, it was later named as C-reactive protein.
CRP belongs to the pentraxin family of proteins, so called because they form a cvcic
pentamer composed of five identical non-glycosylated sub-units, non-cavalent bound and
organized in a very stable discoid-like structure. Another important member of this
family is the serum amyloid P component. These proteins are conserved throughout
vertebrate evoludon, suggesdng that CRP has a central role in the immune response.39’4°
CRP binds to several poÏvsaccharides and peptido-polysaccharides present in bactena,
fungi and parasites in the presence of calcium. These complexes activate the classical
complement pathway, acting as opsonins and promoting phagocytosis. Together with
complement components, CRP is the only acute phase protein directly involved in the
clearance of micro-organisms. In vitro, CRP stimulates cell-mediated cytotoxicity through
activation of neutrophils, promoting platelet degranulation and enhancing NK ceil
activity. Under physiologic conditions, CRP binds to small nuclear nbonucleoproteins,
suggesdng a direct role in the removal of necrouc
CRP is detected wi± low levels in die serum of the normal human population, with a
median of 0.8 mg/L and it is below 10 mg/L in 99% of normal samples. Levels above
these values are abnormal and indicate die presence of a disease process.
As with other acute phase proteins, CRP is mainly synthesized by the liver, mainly in
response to IL-6. TNF-Œ and IL-1 t3 are also regulatory mediators of CR2 synthesis.
During acute inflammatory or infectious states, changes in CR2 levels are determined by
die rate of synthesis and is not modified by any therapy that does not affect die evoludon
of the disease 0f interventions such as renal replacement therapy.4°
10
Elevations in serum CRP are seen in most invasive infections, including bacterial and
fungal infections, even in immunodeficient patients.4° By contrast, CRP concentrations
tend to be lower in most acute viral infections.40 Nevertheless, this is not absolute and
sensitivides and specfficides vary among swdies. There is limited knowledge of CRP
behavior in parasitic infections, but some protozoan parasidc diseases sucli as malaria,
pneumocystosis and toxoplasmosis are also able ta cause marked rises in CRP. In
chromc infections, such as tuberculosis and leprosy, although abnormal, CR2 levels are
usually only modestly elevated. In addition ta infection, there are several other conditions
that are associated with substandal increase in CRP levels, which include trauma, surgery,
burns, tissue necrosis, immunologically mediated inflammatory diseases, crystal-induced
inflammatory diseases and advanced cancer. However, some inftammatory disease, such
as systemic lupus erythematosus, systemic scierosis, dermatomyosids, Sjôgren’s disease,
ulcerative colids, leukemia and graft-versus-host disease are associated with only minor
elevadons of CRP. For reasons unknown, the acute phase response mduced by these
diseases is unable ta raise the CR2, due to failure of synthesis rather than increase in
clearance. However, in response ta infection these patients are stiil able ta mount a
major CR2 response. This property is used ta distinguisli infection from a ftare-up of the
underlying disease process.4°
Besides its use in the diagnosis of sepsis, CR2 has also been associated to disease severity,
with increaed levels in patients wi± septic shock compared ta patients with sepsis
alone.34 h lias also been evaluated as a prognostic marker. Non-survivors had a median
CR2 concentration signiflcandy bigher than sunrivors.41
Accumulating data pathologically link atherosclerosis and die inftammatory response ta
vascular injury. Several prospective studies have demonstrated a direct correladon
between acute myocardial infarcdon, rise in CR2, posdnfarcdon adverse events, and
subsequent infarct size. Not only that, but a positive association has been found between
CR2 levels and risk of developing peripheral artenal disease,38 suggesdng that CR2 would
be a good marker for vascular disease in asymptomatic patients. In these situations, CR2
levels are signfficandy lower (10O dmes) than in acute inflamrnatory processes and is
measured with higli-sensinve assays.42 There is no current evidence that lowering CR2
necessarily reduce cardiovascular event rates; however, many interventions known to
reduce cardiovascular risk,12 including the use of anti-cholesterol drugs (stadns),43 have
been linked to lower CRP levels.
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Meta-anaysis technique
Interest in medical applications of meta-analysis has increased significandv in recent years,
although meta-analytic procedures have been widely employed in the social sciences since
the early 1970s.
The National Hbrary ofMedicine defmes meta-analysis as “a quantitative method of
combining the resuits ofindependent studies (usually drawn from the published
literawre) and synthesizing summaries and conclusions which may be used ta evaluate
therapeutic effectiveness, plan new swdies, etc. It is often an overview of cimcal trials.”
Meta-analysis is a systematic method that uses statistical analysis for extracting,
comparing, and combining resuits from independent studies ta get quantifiable outcomes.
Meta-analysis should be viewed as an observational study of the evidence; the steps
involved are similar ta any other research undertaking: formulation of the problem ta be
addressed, collection and analysis of the data, and reporting of the results. The method
consists of a thorough literature review, calculation of an effect size for each study,
determination of a composite effect size from the weighted combination of individual
effect sizes, and calculation of a fail-safe number (number of unpublished studies with
opposing conclusions needed ta negate the published literature) ta assess the certainty of
the composite size.
Considerable amount of money is spent on chnical research. However, findings are not
aiways implemented in routine clinical practice. Systematic reviews of rigorous studies
provide the best evidence of the effectiveness of different strategies for promoting
behavioral change.45’ Practicing evidence based medicine is one way for cinicians ta
keep up to date with the exponential growth in medical literature.47
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Meta-ana/ysis ofdiagnostic tests versus randomied controtted trials
Systematic reviews of tests are undertaken for the same reasons as systematic reviews of
therapeutic interventions: to produce estimates of performance based on ail available
evidence, to evaluate the quality of published swdies, and to account for variation in
findings between studies. Reviews of studies of diagnostic accuracy, in common with
systematic reviews of randomized controlled trials, involve key stages of question
definition, litera ture searcbing, evaluation of studies for eigibffity and quality, data / /)
extraction and data synthesis. However, the det1s thin some of the stages differ.48
Systematic reviews of randomized controlied trials are ofren justified on the grounds that
they increase statistical power: by assimiladng participants recruited to a series of trials,
they increase our ability to detect small but dinicaily important differences in outcomes
between treated and control groups. Statistical power is rarely discussed in studies of
diagnostic accuracy as they do not compare two groups, and they do not formally test
hypotheses. However, increasing sample sizes by pooling the resuits of several studies
provides an opportunity to improve the precision of these estimates, and to investigate
the consistency of test performance and compare resuits between studies of different
designs and from different settings.48
Studies of test performance (or accuracy) compare test resuits between separate groups of
patients with and without the target disease, each ofwhom undergoes the experimental
test as well as a second “gold standard” reference test. The relationship between the test
resuits and disease status is described using probabilistic measures, such as sensitivity and
specificity. is important that the results of the reference test are very close tu the truth,
or else the performance of the experimental test will be poorly estimated. To achieve
this, reference tests sometimes involve combimng several pieces of information.48
There are three major ways in wbich systematicaily reviewing studies of diagnostic
accuracy differs from reviewing therapeutic interventions: the choice of search terms for
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electronic literature searches, the criteria for the assessment of swdv qualiry, and the
methods for the statistical combinadon of results.48
Electronic database searches for swdies of diagnostic accuracv can be more difficuit and
less productive than those for randomized trials. Occasionally a simple search using just
the test name wffl prove to be sensitive, but many diagnostic technologies (such as
ultrasound, x ravs, and serologv tests) are used across a variety of fields in medicine, so
that a mixture of appropriate and inappropriate studies wffl be retrieved, and the search
will not be specific. Including terms for the disease is the searcli may help.48 Several
MeSH terms have been suggested for locating studies of diagnostic accuracy.
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Possibte bias ofmeta-anaysis ofdïagnostit’ tests
The ideal study sample for inclusion in a review is a consecutive (or randomly selected)
series of patients recruited from a relevant cinical population. Selection bias may be
introduced by selecting patients for inclusion in a non-random manner. This can present
as a form of spectrum bias that arises whenever the swdy population is flot representadve
of the spectrum of disease within which the test .vi11 be applied in practice.
In practice, Ït S easier to include patients with or without the disease as separate groups,
as in a case-control study. This Can lead to bias, however, as detecuon rates vary
according to the severity of the disease, and the chances of falsely positive diagnosis wiil
vary between patients according to the alternative disease that they do have. Choosing
cases that have already been idendfied as having the disease will mtroduce bias into the
estimates of test sensitivitv, choosing controls that are completelv healthy will introduce
bias into the estimates of test specificity.48
As well as being selected in a correct manner, it is also important that the swdy samples
are selected from similar healthcare settings. This is more a matter of the applicabffity of
study rather than study quality. Importantly, it is possible that the spectrum of disease
and alternative diagnoses varies between different points in the health care referral
process, such as primary and secondary care. As the sensitivity and specificity might not
be constant across the spectrum of the disease or across the alternative conditions, the
observed values of test sensitivity and specfficity in die rwo samples might differ. This
variation lias nothing direcdy in do with disease prevalence within the study group:
although it is likely that the prevalence of die disease wffl also differ between points in a
referral process, the obsenred sensitivity and specificity will only change if the
proportionate mix of die spectrum of diseased and non-diseased patients varies as well.
Variation in prevalence may be a hint of die presence of spectrum bias, but it is not its
cause.48
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The selecuon of a good reference standard is crucial. Tvpically the reference standard is
considered a “gold standard”, and the comparison is one-sided: if there are any
disagreements between the reference standard and the experimental test it is always
assumed that the experimental test is incorrect. It is important that the two tests are
based on independent measurements. In some circumstances the reference diagnosis
may be made on the basis of a battery of cinical tests and other available cinical
evidence. If this is the case, the batterv of resuits should flot incÏude the experimental test
resuit, or else the diagnostic accuracy viil most likely be overestimated. Such an effect is
knoWn as incorporation bias.48
Verification bias is a problem when the decision to undertake the reference investigation
is influenced by the resuit of the experimental test or other factors wbich indicate that die
disease is unlikely. There are nvo levels ofincomplete verification: partial verification
where flot ail participants undergo die reference investigation, and differendal verificadon
where different reference tests are used according to the results of the experimental test.
Partial venfication bias usuaily leads to the numbers of true negative and false negative
participants being reduced, so that sensitivity is biased upward and speciflcïty biased
downwards. In contrast, differendal verificadon bias may lead to both estimates being
biased upwards.48
Blinding involves each test being undertaken and interpreted without knowledge of the
resuits of the other. This is especiailv important for tests that involve subjective
judgements, such as those that rely on human perceptions in interpredng images and
sounds.48
Another important aspect of quality is whether both diagnostic tests were undertaken
before any treatment was started. ‘Vhere this does not occur, a treatment paradox can be
introduced: patients who are diagnosed with the disease at die flrst test can be treated and
cured before the second test, and misclassifled as false positives or false negatives
depending on which tests vas used first.48
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Inclusion of the test resuits of ail participants in the analysis is important. Many tests
report some resuits as being in agry-one, or occasionally as testfaiÏures. Although
including these outcomes in an analysis is not aiways straightfonvard, ignoring them will
present a test more favourably than is justified.48
Ideally, a study report should include clear descriptions of the reference and the
experimental tests, with definitions of positive and negative outcomes for both, and
descriptions of demographic characteristics, co-morbidities, the source and referral
bistory of the patients. Lijmer et aL° provided evidence that case control study designs
radier than cinical cohort overestimated diagnostic accuracy by a relative diagnostic odds
ratio of 3.0 (95% CI 2.0 - 4.5), being the greatest potenual source ofbias. Studies using
differential reference standards were also found to overestimate diagnostic performance
compared to those using the same reference standard for both, whilst partial verification
did not introduce a consistent effect. Unblinded studies were on average more likely to
overestimate diagnostic accuracy. They also noted that the omission on repordng specific
details of a swdy vas associated with systematic differences in results.48
The problem of publication bias are more difficuit: there are no studies in the literature
which estimate rates of publication bias for diagnostic accuracy studies, and such
investigations are difficuit to undertake, as studies cannot easily be identified before they
are undertaken. Also, there is no way to investigate whether or flot the studies identified
are a biased sample. Some authors have suggested that publication bias may in fact be a
greater problem for studies of diagnostic accuracy than for randomized controlled trials.50
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I—Ieterogenei ofstudies in a mela-ana!ysis
Another important source of variation to consider in meta-analyses of diagnostic accuracy
is the variation introduced by changes in diagnostic threshold. The studies included in a
systematic review may have used different thresholds to define positive and negative test
resuits. Some may have done this explicitly, for example by varying numerical cut-points
used to classify a biochemical measurement as positive or neganve. for others there may
be naturally occurring variations in diagnostic thresholds between observers or between
laboratories. The choice of a threshold may also have been determined according to the
prevalence of the disease — when the disease is rare, a low threshold may have been used
to avoid large numbers of false positive diagnoses being made. Unlike random variabffity
and other sources of heterogeneity, varying the diagnostic threshold ber.veen studies
introduces a particular pattern into the ROC plot of study resuits. If such variation is
present, the points will demonstrate curvawre that parallels to the underlying ROC curve
for that test. The approach to combining swdies in these situations involves denving die
best-fitting ROC curve rather than summarising the resuits as a single point.48
The simplest method of combining studies of diagnostic accuracy is to compute weighted
averages of die sensitivity, specificities or likelihood ratios. This method should only be
applied in the absence ofvariability of the diagnostic threshold. The possibility ofa
threshold effect can be investigated before this method is used, both graphically by
plotting the study resuits on an ROC plot, and statistically, by undertaking tests of
heterogeneity of sensitivities and specificities and investigadng whether there is a
relationship between them. The homogeneity of the sensitivities and specificities from
the studies can be tested using standard chi-squared tests as both measures are simple
proportions. Calculation of the correlanon coefficient between sensitivities and
specificities will test whether they are related, as would be die case if there vas variation
in the diagnostic threshold. If an association between die sensitivities and specificities is
detected, use of weighted averages will lead to underestimation of diagnostic
performance, as the point corresponding to the average of the sensiiivities and the
average of the specificities aiways fails below the ROC curve. Note that when the studies
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in the systematic reviews have srnall sample sizes, tests for heterogeneity and correlation
have low statistical powcr, and therefore a threshold related effect may exist but rernain
undetectccl by the statistical tests.1
1f there is any cviclence that die diagnostic threshold varies between the studies, the best
summary of the rcsults of the studics xviii be an ROC curve rather than a single point.
Diagnostic tests where the diagnostic odds ratio is constant regardiess of the diagnostic
threshold have symmetrical ROC curves. In these situations, it is possible to use standai-ci
meta-analysis rncthods for combimng odds rations to estirnate the common diagnostic
odds ratio, and hence to determine the best-fitnng ROC curve. Once the surnrnary odds
ratio, DOR, bas been calculateci the equation of the corresponding ROC curve is given
by: sensitivitv = 1 / { Ï +Q /(DOR x [(i-specfflcity)/specfficity]) } .°
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Aloses ancÏ SAt/3iro methocit/or estimation oftmmnay ROC ciii’ves
Difference between studies in patient groups, test execution and study design can
introduce vanability in diagnostic odds ratios. Both methods ofpooling odds ratios can
be cxtcnclccl to investigate the possible importance of these features. If it can be assumed
that the summary ROC curves arc symmetrical, the impact of other factors can be
investigated using standard mcthods of mcta-regression for odds ratios. Alternatively,
Littcrnberg-Moses regression method can be extended by adding a covariate to the
regrfesslon ecpatlon for cach potential effect modifier. The exponential of each of these
tcrms estimates multiplicative increases in diagnostic odds ratios for each factors.48
\Vhen die diagnostic odds ratio changes with diagnostic threshold, asymmetrical ROC
curves occur. Litternberg, Moses and Shapiro proposed a method for fitting a whole
family of summary ROC curves which allow for variation in DOR (summary odds ratio)
with thrcsho1d.” 2
‘flic method considers the relationship betxveen the DOR and a surnrnary measure of
diagnostic threshold, givcn by thc procluct of the odds of truc positive and the odds of
false positive resuits. As a diagnostic threshold decreases, the numbers of positive
diagnosis (both correct and incorrect) increases, and die measure of threshold increases.
‘flic diagnostic odds ratio is clcnoted by D, and die logarithm of the measure of
threshoid by S. D and S cati be caicuiated from the truc positive rate TPR and false
positive rate (FPR using the folloxving ecluations:
S in { jTPR/(1-’J7R] x FPR/(1-FPR]} = iogit (TPR + logit (FPR
D in (DOR in { [TPR/ (1- TPR1 x [(1- FPR / FPRI } in [(LR + ve) / (LR — ve]
logit (TPR) - iogit (d’PR, \vhere /ogit indicates the Io,g ofthe ocÏdç, as used in logistic
regre ssi on.
Littcnberg anci Moses’ method first consders a plot of the iog of the diagnostic odds
ratio (D) against the measurc of thrcshold (S) calculated for each of the studies. They
21
propose computing the best fitting straight lime through the points of the grapli. If the
equation of the fttted lime is given by: D = a + bS testing the significance of the estimate
of the siope parameter b testes whether there is significant variation in diagnostic
performance with threshold. If the lime can be assumed horizontal, the diagnostic odds
ratio does mot change with threshold, and the method yields symmetrical ROC curves,
similar to those obtained from directly pooling odds ratios. However, if there is a
significant trend in the diagnostic odds ratio with diagnostic threshold then ROC cunres
are asymmetrical, the summarv ROC curve being calculated as:
sensidvity = 1/[1 + (1/& x (1— specificity/specificity)1 )1]•48
Once S and D have been calculated for each study in the meta-analysis, a simple least
squares regression is used to fit a straight lime to the points. The regression lime is then
back-transformed into sensitiviry and specificity. À confidence interval (CI) on the
summarv ROC curve can be obtained by back-transforming the CI form the linear
regression.53
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Thepresent stu4y
Previous studies have suggested that both PCT and CRP could be promising diagnostic
markers for bacteriai infections.17’ 29, 30, 33, 34, 37, 38, 40, 54-134 However the accuracy of these
markers lias varied across studies, especially as a resuit of limitations in sample size and
differences in studv designs. In order to adequately summarize the udlity of these
markers in cinical practice, we carried out a meta-analysis and svstematically reviewed
studies that simultaneously invesdgated these tests as markers for bacterial infection.
Chapter II
Article
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AB STRACT
Context: Procalcitonin and C-reactive protein have been advocated to diagnose bacterial
infection. Their accuracy remains uncertain.
Objective: Meta-analysis of published studies to compare the accuracy of procalcitonrn and
C-reacdve protein as diagnostic markers of bacterial infection.
Data Sources: Studies published in MEDLINE (1970 — 2002) that evaluated procalcitonin
and C-reactive protein for the diagnosis of bacterial infections were identified. Cross
references were reviewed.
Data Selection: 351 tides were identified; 110 prospective studies among hospitalized
patients were evaluated. Articles were selected by three reviewers.
Data Extraction: Data were extracted in 2 by 2 tables. Authors of articles were contacted
to verify data.
Data Synthesis: 12 articles were included (1497 patients). Data were summarized using
linear regression methods and summary receiver operating characteristic curves were
generated. Procalcitonin was more sensitive than C-reactive protein: 0.88 [95% CI 0.80 —
0.93] versus 0.75 [95% CI 0.62 — 0.84] for differentiating between bacterial and non-infective
causes of inflammation; difference 0.13 [95% CI 0.08 — 0.17], p < 0.05. Procalcitonin vas
also more specific: 0.81 [95% CI 0.67 — 0.90] versus 0.67 [95% CI 0.56 — 0.77]; difference
0.14 [95% CI 0.08 — 0.20], p <0.05. The Q value for procalcitomn vas higher than for C
reactive protein: 0.82 and 0.73 respectively. The sensitivity for differentiating betwecn
bacterial and viral infections was higher for procalcitonin than for C-reactive protein (0.92
[95% CI 0.86 — 0.95] versus 0.86 [95% CI 0.65 — 0.95]); difference 0.06 [95% CI 0.005 —
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0.11], p < 0.05. The specificities were comparable (0.73 [95% CI 0.42 — 0.91] versus 0.70
/
[95% CI 0.19 — 0.96]); difference 0.03 [95% CI tLO4—0.1], p > 0.05. The Q value was
biglier for procalcitonin: 0.89 versus 0.83 for C-reactive protein.
Conclusions: The diagnostic value of procalcitonin was higher than the one for C-reactive
protein in hospitalized patients. Procalcitonin should be favored for use in cimcal practice.
KEY WORDS
meta-analysis, systematic review, bacterial infections, inflammation, sepsis, diagnostic tests,
C-reactive protein, procalcitonin
27
INTRODUCTION
Bacterial infections are a major cause of hospitalization, intensive care unit admission and
mortality. Bacterial infections often activate the systemic inflammatory network, causing
systemic inftarnmatory response syndrome (SIRS). This acute activation as a resuit of
bacterial, fungal, viral and/or parasitic infections is referred to as sepsis.1 Bacterial infections
are the leading cause of systemic inflammation and sepsis.2 Because the presentations may
be similar, a major challenge in cinical practice is to accurately distinguish between SIRS and
sepsis. Around 700,000 cases of sepsis are reported annually worldwide and account for
about US$ 15 billion in health care costs in the U.S. alone.3 Recent data from the Centers
for Disease Control (CDC) indicate that the incidence of sepsis is increasing by an average
of 16% a year in the U.S.. Dunng the 20-year penod from 1979 to 1999, the incidence of
sepsis increased by more than 329%. It went from 78 to 259 cases per 100,000 people. The
associated mortality rate is decreasing, though, dropping from 29% ni 1979 to l7.4% in
1999. However, because of the increased incidence of sepsis, the total number ofpeople
who die from sepsis continues to increase each year.2
Recognizing sepsis and bacterial infections is important in order to initiate timely and
appropnate treatment. The increase in antibiotic resistance due to inappropriate use of
broad-spectrum antibiotics makes the identification of the cause increasingly cntical.
However die early diagnosis of bacterial infections is difficuit and sometimes chaflenging. It
requires demonstration of bacteria in sterile sites, either by finding pus or a significant
amount of bacteria by Gram’s s tain or culture, or by showing the presence of bacterial
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genome by PCR. Presendy, diagnosis by using bacterial culture methods is the reference
standard. However, its udlity is often hampered by delays in obtaining the resuits (usually at
least 24
- 4$ hours). Hence the identification of suitable markers for the early diagnosis of
bacterial infections is paramount.
Two potential markers, procalcitonin (PCT) and C-reactive protein (CRP), are presendy
being widely studied to investigate their accuracy vis-à-vis the diagnosis of bacterial
infections. PCT is die pre-hormone of calcitonin. Under physiologic conditions, serum
concentration ofPCT is negligible or undetectable.4 CRP is an acute phase reactant that
tises whenever an inflammatory process is present. Previous studies have suggested that
both PCT and CRP could be promising diagnostic markers for bacterial infections.
However the reported diagnostic accuracy of these markers has varied across studies. This is
probably due to differences in study designs and/or limitations in sample size. In order to
adequately summarize die accuracy of these markers, we carried out a meta-analysis and
systemadcafly review of studies that simultaneously invesdgated PCT and CRP as markers
for bacterial infection.
29
METHODS
Retrievin<g tue literature. Ail studies published in MEDLINE from January 1, 1970 through
May 30, 2002 that evaluated PCT and/or CRP for the diagnosis of bacterial infections were
identified using pre-established scarch strategies. Referring to at least one keyword per
category, cross-searcbing of the following five categones were donc using a Boolean strategy:
(1) type of study (descriptive study or diagnosis or epidemiological study or meta-analysis or
multicenter study or prospective or review-literature or reproducibffity or test or validation);
(2) site of the study (critical care or hospital or intensive care); (3) subjects (human); (4) test
(C-reactive protein or interferon or interleukin or procalcitonin or wbite blood ccli count or
sedimentation) and (5) disease (infection or cross infection or hospital acquired infection or
meningitis or multiple organ dysfuncdon syndrome or MODS or pneumonia or sepsis or
septicemia or septic shock or systemic inflammatory response syndrome or SIRS). The
bibliography of the relevant articles were further cross-checked to search for articles flot
referenced in MEDLINE.
Setection ofStudies Inclusion and Exclusion Criteria, and Data Extraction. Studies that
prospectively and simultaneously evaluated both PCT and CR2 as diagnostic markers for
bacterial infection in hospitalized patients were evaluated. Studies examining ail age groups
were included. Retrospecuve sW±es, reviews, animal studies ami snidies with incomplete
data were excluded. The tities and abstracts of ail pertinent articles were reviewed by three
independent reviewers (LS, FG, JL) to identifr potentiaily relevant studies. Discrepancies or
disagreements, if any, on the inclusion or exclusion of studies were resolved by consensus.
Whenever possible, the raw data from the articles were used to construct 2 by 2 tables.
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When raw data was unavailable, the tables were constructed using given measures of
sensitivity and speciflcity. Some studies reported the sensitivity and specificity at many
cutoff points. In such instances, we chose the cutoff point with the best efflciency value,
which is found by dividing the sum of cases classffied as truc positives and truc negatives by
the total number of cases.5 Authors ofindividual articles were contacted and asked to
complete or correct any missing or incorrect information.
,Quatiy Assessment. We evaluated the methodological quality of the included studies by
applying the critena for assessing randomized clinical trials design-related bias described by
Chalmers et al.6 Four aspects of each study were evaluated for the assessment of the quality
of the research: (1) basic descriptive material; (2) study protocol; (3) analysis of the data and
(4) data potentiafly useful for combination of several randomized dinical trials resuits. The
latter three aspects were graded and a score was awarded to cadi item under each aspect.
Subsequendy, an overail quality index for each study was obtained by adding up the item
scores and dividing by the total possible score. Rate of agreement among the three
independent reviewers was calculated for cadi item and expressed as a percentage.
Mela-anaLvsis. The meta-analysis approach that uses linear regression techniques to combine
data from independent studies evaluating similar diagnostic test/critena as described by
Moses and Shapiro was udlized.7 To create die summary receiver operaung charactenstic
(SROC) curve, we frrst calculated the truc-positive rate (TPR) and false-positive rate (FPR)
from each individual study from die reconstructed 2 by 2 tables. These rates were tien
converted tu their logistic transform (log [ITR/f-TPR] and log [FPR/1-FPR]). The sum (S)
and the difference (D) of these logisdc transforms were calculated for each study as well as a
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regression lime fitted to these points, with D as the dependent variable and S as the
independent variable (D = a + bS). Based on this equatiom, the values of semsitivity and
specificity required to construct the SROC curve were then calculated as: sensitivity = 1/(1
+ 1/ea/(l_b) x (1
— specificity/specificity)1 +b)I(1_b) The resulting values were then plotted in
the SROC space to obtain the SROC curve. We took into account the differences in sample
sizes among the studies by weighting each observation by the reciprocal of the variance of D
and performing weighted regression. To further compare the accuracy between PCT and
CRP, we calculated the Q values from the SROC cunres obtained for each of these critena.
Tins value represents the intersection point of the SROC curve with a diagonal lime from the
left upper corner to the right lower corner of the ROC space, where sensifivity and
specificitv are equal. A higher Q value indicates higher accuracv.
32
RESULIS
From the initial search of the MEDLINE database (January 1, 1970 to May 30, 2002), a total
of 351 publications were retrieved. 0f these, 110 smdies that suggested thatPCT and/or
CRP were performed in hospitalized patients with bacterial infection were selected.srI7 On
reviewing these abstracts, 21 artic1es977 that prospectively and simultaneously evaluated
PCT and CRP were identifled. Another article118 was found after searching the
bibliographies and other related information sources, including textbooks. On detailed
review of these 22 articles, 12 of them were deemed appropnate for the meta-analysis.106117
Four of the 22 studies were excluded 100, 102-104 because swdy design was not geared towards
the evaluation of the role of PCT and CRP as diagnostic markers of infection, and other
outcomes such as prognosis, mortality or PCT kinetics was evaluated. Six other studies were
excluded because die swdy population and data extraction was not clear,105’8 die study
population was an extension of another published study,97’98’10’ or because no control group
was evaluated.99 Whenever possible, authors were contacted and asked to verify the data
extracted from the original article. They were also asked to provide any available
supplementary information pertaining to the critena used for diagnosing infection. Resuits
of each individual swdy included in the present meta-analysis derived from their 2 by 2
tables are presented in Tables I through 4.
The methodological evaluation of swdy quality is presented in Table 5. The average quality
index was 62/101. When evaluating the study protocols, patient selection was always well
descnbed and haif of the studies included consecutive patients. Test deflmtion, description
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and value were adequatelv described in most of the swdies. Assavs were blindly performed,
but there vas no blinding when samples were drawn from the patients. The accuracy of the
tests vas calculated in ail studies, largehr by construcdng a ROC curve. No description vas
available on whether the statistician who performed the analyses vas blinded to the
diagnosis. Resuits were presented in a non-uniform way among the included swdies. There
were a total of 324 items rated to evaluate the quality of the studies. Complete agreement
between reviewer scores was seen in 86.4% ofthe items (280/324); in 12.7% (41/324) there
was agreement between two reviewers, and complete disagreement was obsenred in less than
1% (3/324).
In ail included swdies PCT was measured by an immuno-luminometric assay (ILMA) with
the commercially available LUMItest PCT (distributed by BRAHMS Diagnostica GmbH,
Berlin, Germany). However, CRP concentrations were determined using several different
techniques and assays. They were: a laser nephelometric technique101 (BN 100, Iviedgenix
Diagnostics, Fleurius, Belgium),106’m Image analyser, Beckman,107 immunonephelometric
method (BNA analyser, Behring Werke AG, Marburg, Germany),2 enzymatic
heterogeneous sandwich inimunoassay (Vitros 950 analyser;Johnson andJohnson,
Rochester, New York, USA),108 EMIT C-reacuve protein assay G. Merck Diagnostica,
Zûrich, Switzerland),° Vitor 9501 RC System, Ortho-Clincal-Diagnostics GmbH,
Neckargemtind, Germany114 or direct immunotrubidimetry Çrina-QuantT1, Boehringer
Mannnheim, Germany).”6
Bactenal infections were mainly determined by isolation of pathogen from blood and/or
other sterile sites, although charactenstic clinical and/or radiological presentation was also
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used for the diagnosis. Viral culture and anti-virai or anti-bacterial antibody titers were used
in some studies to confrm an infectious diagnosis. Biopsy and autopsy were rarelv
performed. Estimates of sensitivit and specificity of the different tests evaluated are shown
in Tables 1 through 4. One swdy108 had three groups of patients (bacterial infections, viral
infections and non-infective causes of inflammation) and vas analyzed in both groups
presented below.
The SROC curves for PCT and CRP are plotted over the domain ofTPR and FPR in Figure
I for 10 studies (905 patients) included in the meta-analysis that evaluated PCT and CRP as
diagnostic markers for bacterial infections compared with non-infective causes of
inflammation. The SROC cunre provides evidence on the individual contribution of each
swdy to the regression analysis. PCT has signiflcandv bigher accuracy as compared to CRP
in the discrimination between bactenal infections and non-infective causes of inflammation.
Pooled sensidvity for PCT was 0.88 [95% CI 0.80 — 0.93] versus 0.75 [95% CI 0.62 — 0.84]
for CRP. The difference in sensitivities vas 0.13 (i.e. 13%) [95% CI 0.08
— 0.171, p < 0.05,
therefore significant. Pooled speciflcity for PCT was also higher than the one for CRP: 0.81
[95% CI 0.67 — 0.90] versus 0.67 [95% CI 0.56 — 0.77], respectively. The difference in
specificities was 0.14 (i.e. 14%) {95% CI 0.08 — 0.20], p <0.05, therefore sigrnficant. This
was confirmed on calculation of the Q values, which was higher for PCT (Q = 0. 82 [95%
CI 0.64 — 0.99]) than that for CRP (Q = 0. 73 [95% CI 0.64 — 0.82]).
In figure 2, the SROC curves for PCT and CRP are plotted over the domain ofTPR and
FPR for 3 studies (592 patients) included in the meta-analysis that evaluated PCT and CRP
as diagnostic markers for bacterial infections compared with viral infections. PCT vas also
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significantly better than CRP for differendating between bacterial and viral infections.
Pooled sensitivity for PCT vas 0.92 [95% CI 0.86 — 0.95], compared to 0.86 [95% CI 0.65 —
0.95] for CRP. The difference in sensitivides was 0.06 (i.e. 6%) [95% CI 0.005 — 0.11], p <
0.05, therefore significant. Pooled specificides were however comparable: PCT 0.73 [95%
CI 0.42 — 0.91] versus CRP 0.70 [95% CI 0.19 — 0.96]. The difference in specificides was
0.03 (i.e. 3%) [95% CI -0.04 — 0.1], p > 0.05, therefore flot significant. The Q values
calculated from the curves were higher for PCT (Q = 0. 89 {95% CI 0.82 — 0.96j) than that
for CRP (Q 0. 83 [95% CI 0.81 — 0.85]), suggesdng that in terms of overail accuracy, PCT
is better than CRP when differendadng between bacterial and viral infections.
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DISCUSSION
Early identification of bacterial infections is stiil a challenge for clinicians. It usually requires
bacterial culture resuits for the definitive diagnosis, which may take up to at least 48 hours to
be available. Identification of an early marker would therefore be extremely useful. Based
on our systematic review and meta-analysis, we observed that PCT was, in general, a more
accurate marker for bacterjal infection than CRP. This vas observed both when
differentiating between bacterial infections and non-infective causes of inflammation and for
differentiating between bacterial and viral infections.
PCT appears to be a promising marker. Under physiologic conditions, PCT is denved from
the preprocalcitomn, secreted by the C-cells of the thyroid in response to hypercalcemia.4
The mechanism proposed for PCT production following inflammation and its role are stiil
not completely known. It is believed that PCT is produced by the liver119 and bv penpheral
blood mononuclear cells,12° modulated by Upopolysaccharides and sepsis-related cytokines.
Following stimulation, PCT secretion begins witbin 4 h, peaks at 8 h, remains elevated at 24
h119’121’122 and clears when the insuit appears to be under control.’23 In addition, the kinetics
ofPCT are very stable. The assay is relatively easy to perform and the test result is available
within two hours, permitting inclusion of the resuits in short-term dinicai decision making.
The cost of the test is moderate (approximately US$ 1O).b07
PCT concentration seems to correlate with severity of disease, with levels bigher in patients
with severe sepsis than in those with sepsis alone.49’124 PCT concentration also seems to
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correlate with severitv of organ dvsfunction, as defined by different scoring systems, such as
SOFA (sepsis-related organ failure assessment),’25 and APACHE II (acute physiologv and
chronic health evaluation II) or survival.110116126 In a baboon sepsis model, PCT
concentrations were significandy lower in sunrivors than in non-survivors.127 These data
suggest that serum PCT could therefore be used not only to diagnose, but also to monitor
disease activitv in patients with sepsis, severe sepsis and septic shock. Continuously
increasing plasma PCT levels usually indicate that the systemic inflammation has not
subsided, the infection is flot under control and/or the therapeutic measures are flot
effective. These patients are more likely to have a poorer prognosis)128 Interestingly, PCT
may also have a non-beneficial effect; in vivo experiments in hamster endotoxin shock models
showed that PCT administered to septic animais increased mortality and that PCT antiserum
protected the animais from the lethal effects of sepsis.129 The reasons for tins are unclear.
CRP is ftequendy used to diagnose bacterial infections, especially in European countries.37
CRP is synthesized by the liver, mainly in response to IL-6, but also in response to TNF-Œ
and IL-lb. IL-6 and IL-l are cytokines produced flot only during infection, but also in many
types of inflammation such as vasculitis, rheumatoid arthritis, nephritis, etc.13° It is thought
that CRP rises nonspecifically whenever an inflammatory process is present, and often will
flot or cannot further increase if die condition becomes more severe.’°7 Following
stimulation, secretion starts within 4
- 6 h, doubling every 8 h but peaking only after 36 h. It
functions by binding to polysaccharides in bacteria, fungi and parasites and activating the
classical complement pathway. Recently, CRP has been shown to predict incidents of
myocardial infarction, stroke, peripheral arterial disease, and sudden cardiac death.13° The
3$
assay for CRP is easy to perform, often automated and lias a reladvely low cost
(approximately US$ 5)107
We must underline some strengths of this systematic review. Decisions on inclusion or
exclusion were based on consensus of three independent reviewers, giving more credibility
to the resuits. There was a high agreement fate among reviewers in every step of this meta
analysis. Authors from individual papers were contacted and asked to confirm or correct the
information retained from the original paper. The response fate from the contacting authors
was notably high (66.7%), giving additional strength to the data analyzed.
The validity of a dimcal trial depends on appropriate allocation, interpretation and
application of the resuits, handling ofwithdrawals, blinding and statistical analysis.6 As
would be expected, none of the studies included in this review were completely free from all
potential biases and limitations. Nevertheless, most of them were ofgood quality. AIl the
studies selected involved prospective data collection, good description of diagnosis of
infection arid statistical analysis. Haif of the studies recrrnted their patients consecutively,
with minimal withdrawal from the study, thereby minimizing selection bias. Few studies
reported information on blinding, which could potentially have altered the trustworthiness
of the data.
In the studies included in this meta-analysis, PCT and CR2 samples were drawn at admission
or at the moment infection was suspected, together with cultures or other tests deemed
appropriate to diagnose infection. Therefore, there was no verification bias, which could
exist when die decision to perform die reference test (in tins case cultures) is based on the
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resuit of the test under examinadon (PCT and CRP). Description of diagnostic criteria were
identified in the papers and confirmed by contacting the authors. In ail swdies, patients
were allocated to the infected or non-infected group without prior knowledge of PCT and
CRI’ results, minimizing investigator bias that coud occur when invesdgators are flot
blinded to the resuits of the swdy and reference tests. Spectrurn bias was also insigrnficant
because of the nature of this analysis. This bias occurs when diagnostic accuracy is
examined by comparing test results among patients known to have disease (bacterial
infection) and among a group of normal subjects (case control study) as opposed to a dimcal
population covenng the spectrum of causal agents (viral infections or non-infective causes of
inflammation). In most cases, these biases could lead to an inflation of the accuracy of the
test or criteria under study.
A large spectrum of the population vas covered in the meta-analysis, which spanned 30
years of data and ailowed die generalization of the resuits. Swdies included 46 neonates, 638
children and 702 adults in different areas of the hospital; about haif of them were in
intensive care units, both pediatric and adult units. 905 patients were included in die analysis
that compared patients with bacterial infections and non-infective causes of inflammation,
and 592 patients were included in the companson of bacterial and viral infections.
The purpose of conducting a statistical analysis of the extracted data is to determine a
summary esrnnate of effect. In the meta-analysis technique, pooling of resuits across studies
or averaging sensitivity and specificity causes underesdmation of test performance because
die relationsbip between sensitivity and speciflcity is not linear. However, the
underestimation is no more than 2% for each parameter.131 We selected a random effects
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model which assumes that the studies included in the meta-analysis belong to a random
sample of a universe of such studies, since both within-study sampling error (variance) and
between-swdies variation are included in the assessment of the uncertainty (confidence
intenral) of the results of a meta-analysis.
This systematic review has some limitations. The lag urne between the beginning of
symptoms and study entry was not provided in most of the stuclies. It is thus possible that
patients were in different stages of the disease. However, considering that the patients were
not previously treated for bacterial infection, this urne difference should not modify the
diagnostic accuracy of the tests. This meta-analysis does flot evaluate serial measurements of
PCT or CRP for the diagnosis of bacterial infection; li evaluates a one-tirne measurement at
die tirne infection was suspected. Some classification bias was possible when allocating
patients to the infected (bacterial or viral) or non-infected groups. Even in the face of
positive culture resuits, there is not aiways enough evidence to discriminate between
infection and colonization.
The accuracy of diagnostic markers can depend on die specific methods used for their
measurement. Invariably, PCT measurements were performed using the commerciafly
available andbody system (BRAHMS, Henmgsdorf, Germany). This assay is specific and
uses two antibodies that bind to two sites (calcitonrn and katacalcin) of the procalcitonrn
molecule thus mling out cross-reactivity. The reported detection limit of the assay is 0.1
ng/ml while procalcitomn levels of healthy subjects are usually undetectable.132 However,
methods of measurement of CRP largely vaned among the 12 included studies; $ different
methods were used for the CRP quantification. The implications of this variabffity are
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unknown to the final resuit of this meta-analysis. However, each study was included using
its own best cutoff value and the linear regression methods used in the analysis account for
possible threshald differences between swdies.
When performing a literature review, one must consider some degree of publication bias. It
is realistic ta speculate that studies have a higher likelihaod of being published when they are
either of good quality or when they show encauraging results.133 Such a selecuve publication
palicy, particularly that based on encouraging resuits, cauld lead ta an inflation of the
associations that were faund, but there is na method ta contrai far this bias when a
systemadc review is companng the predictive value af twa tests.
This meta-analysis does pravide a reasanable campansan between PCT and CRP and allaws
the investigator or cinician ta decide an the chaice of the most apprapriate test suitable far
bis or her cinical setting. With this swdy, we can conclude that the overail accuracy of PCT
is bigher than that of CRP bath for differentiating between bacterial and viral infections and
between bacterial infections and ather nan-infective causes af systemic inflammation. We
therefore think that PCT is a good marker far bacterial infection and cauld be considered
for widespread use in cinical practice. Hawever, the usefulness of these tests remains ta be
determined.
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TABLES and FIGURES
Table 1. Resuits denved from the 2 by 2 tables of indMdual studies for PCT — bacterial
infections vs. non-infective causes ofinftamrnation
TP/FN FPITN Se 95% CI Sp 95% CI
Aouifi et aI. 06 46/2 8/41 0.96 0.85
- 0.99 0.84 0.70 - 0.92
Enguix et aL 07 19/3 1/23 0.86 0.64-0.96 0.96 0.77- 1.00
*Hatherill et al. ‘° 103/3 9/40 0.97 0.91 - 0.99 0.82 0.68 - 0.91
*MuIIer et aI. 110 52/3 6/40 0.95 0.84 - 0.99 0.87 0.73 - 0.95
*Penel et al. 111 43/14 0/5 0.75 0.62 - 0.85 1.00 0.48 - 1.00
*Rothenbutger et al.
112 12/2 3/42 0.86 0.56 - 0.97 0.93 0.81 - 0.98
Selberg et al. 19/5 3/6 0.79 0.57 - 0.92 0.67 0.31 - 0.91
*Suprjn et al. 49/6 26/14 0.89 0.77 - 0.95 0.35 0.21 - 0.52
*Ugarte et al. ‘ 75/31 36/48 0.71 0.61 - 0.79 0.57 0.46 - 0.68
*VialIon et al. 117 19/2 2/38 0.90 0.68 - 0.98 0.95 0.82
- 0.99
Total (REM Pooled)h 0.88 0.80 - 0.93 0.81 0.67
- 0.90
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Table 2. Resuits denved from the 2 by 2 tables ofindividual smdies for CRP — bacterial
infections vs. non-infective causes of inflammation
TPIFN FPITN Se 95% CI Sp 95% CI
Aouifi et al. ‘° 50/33 4/10 0.60 0.49 - 0.71 0.71 0.42 - 0.90
*Enguix et al. 07 19/4 1/22 0.83 0.61 - 0.94 0.96 0.76 - 1.00
*Hathetill et al. 08 73/0 37/43 1.00 0.95 - 1.00 0.54 0.42 - 0.65
*Mulleretal. 110 41/9 17/34 0.82 0.68-0.91 0.67 0.52-0.79
*Penel et al. 43/24 0/1 0.64 0.52 - 0.75 1.00 0.03 - 1.00
*Rothenburger et al.
112 14/30 1/14 0.32 0.19 - 0.48 0.93 0.66 - 1.00
Selberg et al. “4 19/9 3/2 0.68 0.48 - 0.83 0.40 0.07 - 0.83
*Suprin et al. 115 55/5 19/14 0.92 0.81 - 0.97 0.42 0.26 - 0.61
*ugalie et al. “ 80/26 3/53 0.75 0.66 - 0.83 0.63 0.52 - 0.73
*Viallon et aI. “7 13/3 8/37 0.81 0.54 - 0.95 0.82 0.67 - 0.91
Total (REM Pooled)” 0.75 0.62 - 0.84 0.67 0.56 - 0.77
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Table 3. Resuits derived from the 2 by 2 tables ofindividual studies for PCT — bacterial
infections vs. viral infections
TP/FN FPITN Se 95% CI 5p 95% Cl
*Hatherill et al. 108 103/6 9/8 0.94 0.88 - 0.98 0.47 0.24 - 0.71
Lorrot et al. ° 126/16 36/258 0.89 0.82 - 0.93 0.88 0.83 - 0.91
Schwarz et al. 113 11/0 5/14 1.00 0.72- 1.00 0.74 0.49-0.90
Total (REM PooIed)0 0.92 0.86 - 0.95 0.73 0.42 - 0.91
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Table 4. Resuits derived from the 2 by 2 tables of individual studies for CRP — bacterial
infections vs. viral infections
Total (REM Pooled)’ 0.86 0.65 - 0.95 0.7 0.19-0.96
TP/FN FP[TN Se 95% Cl Sp 95% Cl
Hatherill et al. ‘° 73/2 36/12 0.97 0.90 - 1.00 0.25 0.14 - 0.40
Lorrot et al. ° 122/30 40/244 0.80 0.73 - 0.86 0.86 0.81 - 0.90
*Schwa et al. 113 14/6 1/8 0.70 0.46 - 0.87 0.89 0.51 - 0.99
Criteria Max
Table 5. Quality assessment of the 12 included studies
Thestudyprotoco!
Patient seiection description 3 3
Number of patients seen and
reject 10g
Withdrawals
Test definition
Gold standard used -
description 3 3
Gold standard used - value 10 8.3
Consecutive cases 3 3
Ail test done in ail patients 3 3
Blinded samples withdrawal 3 0
Iinded samples assays 8 8
Prior estimate of numbers:
endpoints, difference of
clinical interest a and f3 3 0
Statistical analysis
Evaluation on major
Regression or correlation
between tests
Rate cf concordance
Kappa score
Accuracy of the test
SROCcurve 4 4
Appropriate statisticai tests 4 4
Statistical ana lysis weli done 4 3.3
Description of withdrawals 4 0
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Papers b Aouifi ‘0 Enguix 107
Hatherill Rothenbur Schwarz
103 Lorrot 09 Mulier 110 Penel 11 ger 112 113 Selberg ‘‘ Suprin ‘‘ Ugarte 110 Viallon ‘‘
2 3 3 3 3 3 3 2.5 2 3 3
3 1
3 0
3 3
0 1.5 3 1.5 3
0 3 3 0 3
3 3 3 3 3
3 3 3 2.5 3
8.3 10 10 10 8.3
o o o 3 3
3 3 3 3 3
o o o o o
8 8 8 8 8
2 2 1.5
o o o
3 3 3
1 3 2.5
5 10 8.3
o 3 0
3 1.5 3
o o o
8 8 8
1.5 3 2.5
3 3 3
3 3 3
3 2.5 3
10 6.7 10
o 3 3
3 3 3
o o o
8 8 8
endpoints
Confidence intervai
o o o o o o o o o o o.
4 4 3 4
3 3 3 0
4 4
3 0
2 2
2 0
2 0
4 4
3 3 4 4 4 4 4
0 0 3 3 0 0 0
O O 0 0 0 2 0 2 0 2 2
o o o o o o o o o o o
o o o o o o o o o o o
4 4 4 4 4 4 4 4 4 4 4
4 4 4 4 0 4 0 4 0 4 4
4 4 2.7 4 2 3.3 3.3 4 4 4 4
3.3 4 2.7 4 1.7 2.7 3.3 4 3.3 4 4
o 4 4 0 4 0 0 0 4 4 4
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‘-landiing cf withdrawals 4 0 0 4 1 0 1 0 0 0 1 1 1
Side effect discussion 3 0 3 0 0 0 0 0 0 1 0 0 1.5
Blinding cf statistician or
analyst 8 0 0 0 0 0 0 0 0 0 0 0 0
Presentation 0f resuits
Dates of starting and
stopping accession 2 2 0 0 2 2 2 2 2 0 2 2 2
Resuits cf prerandomization 2 2 0 1 2 1.7 2 1 2 2 2 2 2
Timing 0f events 4 3.3 4 0 2 3.3 2.7 2.7 3.3 3.3 3.3 2.7 4
Total 101 60.9 56.6 66.5 66.4 61 59.7 49.7 58.4 60.1 61.1 66.9 75
Table 5. Quality assessment ofthe 12 included studies (cont)
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Figure 1. SROC curves comparing serum PCT and CR2 bacterial infections vs. non
infective causes of inflammation
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Figure 2. SROC cunes comparing serum PCT and CRP — bacterial infections vs. viral
infections
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LEGENDS Tables
• Table 1.
TP, number of true positive patients; FN, number of false negative patients; FP number of
false positive patients; TN, number of true negative patients; Se, sensitivity (Se = TP/(TP +
FN)); Sp, specificity (Sp = TN (TN + FP)); 95% CI, 95% confidence interval; REM, random
effects model; *data confirmed by original author
• Table 2.
See legend in Table 1
• Table 3.
See legend in Table I
• Table 4.
See legend in Table I
• Table 5.
Questionnaire adapted from Chalmers et al.6 For each item, resuits are expressed as
average score of 3 reviewers.
b papers included in the meta-analysis
Max, maximal score; SROC, summary receiver operating charactenstic
LEGENDS Figures
• Figure 1.
Each point contributing to the SROC curve represents one study: circtes, PCT; , CRP
• Figure 2.
Each point contributing to the SROC curve represents one study: circtes, PCT; , CRP
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Chapter III
Discussion and Conclusion
Stu4y identification, seÏection anti inclusion in this meta.-ana/ysis
Studj identflcation. Two online searches of the National Ubrary of Medicine MEDLINE
database were performed using the PubMed search engine. The searches covered from
January 1, 1970 through May 30, 2002. The search was completed onJune, 2001. The
search combined medical subject headings (MeSH) in five different categories: (1) type of
study, (2) site of the study, (3) subjects, (4) test and (5) disease, linked by AND
terms. Within each category, medical subject headings were linked by OR terms. The
MeSH terms used were (1) type of study (descriptive study or diagnosis or
epidemiological study or meta-analysis or mufficenter study or prospective or review
literature or reproducibility or test or validation); (2) site of the study (crincal care or
hospital or intensive care); (3) subjects (human); (4) test (C-reactive protein or interferon
or interleukin or procalcitonin or white blood ceil count or sedimentation) and (5) disease
(infection or cross infection or hospital acquired infection or meningitis or multiple organ
dysfunction syndrome or MODS or pneumonia or sepsis or septicemia or septic shock or
systemic inflammatory response syndrome or SIRS).
The tides of the resuffing citations (351) were scanned. The resulting set was further
hmited by exciuding reviews, editonals, or letters. Abstracts of potentially relevant
17 19 29 33 34 37 40 41 54—59,61 64-71,73-87,89-104,106-111,113-117,119-132,134—articles were then retneved (110
162). Additional articles were sought by scanning bibliographies in the reference sections
of selected articles or review articles on diagnosis ofmfection, sepsis, procalcitonin and
C-reactive protein. The authors of pnmary studies identified through literature searches
were contacted by letter, or by email or both, seeking verification of the data extracted, or
additional data not presented in the published study, and to enquire about knowledge of
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unpublished or additional studies. Additional articles suggested by experts on the fleld
also reviewed (1 article63).
Selection ofStudies, Inclusion and Exclusion Criteria, and Data Extraction. S tudies that
prospectively and simultaneously evaluated both PCT and CRP as diagnostic markers for
bacterial infection in hospitallzed patients were evaluated. Studies examining ail age
groups were included. Retrospective studies, reviews, animal studies and studies with
incomplete data were excluded. The tities and abstracts of ail pertinent articles were
reviewed by three independent reviewers (LS, FG, JL) tu identify potendafly relevant
studies. Discrepancies or disagreements, if any, on the inclusion or exclusion of studies
were resolved by consensus. Whenever possible, the raw data from the articles were used
to construct 2 by 2 tables. \Vhen raw data was unavailable, the tables were constructed
using given measures of sensitivity and specificity. Some studies reported the sensitivity
and speciftcity at many cutoff points. In such instances, we chose the cutoff point with
the best efftciency value, wbich is found by dividing the sum of cases classifled as true
positives and true negatives by the total number of cases.’63
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Detaits on studies inctuded in the rneta-anasis
Aouifl et al.54 measured PCT and CRP in 97 consecutive aduits with suspected infection
in the postoperauve course of cardiac surgerv. Fifty-four (54) were proven to have
bacterial infection (17 pneumonia, 16 bacteremia, 9 mediastinitis, 12 septic shock). Serum
PCT vas markedly higher in patients with septic shock (96.9$ ng/mL) compared with a
moderate increase in patients with pneumonia (4.85 ng/mL) and bacteremia (3.57
ng/mL). There vas a low level increase in patients without infection (0.41 ng/mL).
Surprisingly, patients with mediastinitis had low PCT (0.80 ng/mL). They found a
threshold off ng/mL for prediction of infection, with a sensitivity of 85% and specificitv
of 95%; positive predictive value of 96% and negative predictive value of 84%. Serum
CR2 was high in ail patients, without intergroup difference. For prediction of infection
with CR2, a value of 50 mg/L was sensitive (84%) but poorly specific (40%). They
concluded that PCT is highly sensitive and specific for the diagnosis of septic shock in
postoperative patients that are not receiving antibiotics.
Enguix et al.n evaluated PCT and CR2 as diagnostic markers ofbactenal sepsis in 46
critically iII neonates. Twentv-six (26) were conflrmed to have sepsis. With a PCT cutoff
value of 6.1 ng/mL, they found 9$.6°/o of sensitivity and 8$.9% of speciflcity, whik with a
CR2 cutoff of 23 mg/L, they found 95.8% of sensitivity and 83.6% of speciflcity. They
concluded that in criticafly ifi neonates, PCT concentration is a better diagnostic marker
of sepsis than CR2. They also evaluated the value of SAA (serum amyloid), which was
not found to be as good of a marker as PCT.
Hatherifi et al.8° evaluated PCT and CR2 compared to leukocyte count as diagnostic
markers for bacterial infection in 175 criticaily iii children. Forty-three (43) were non
infected controls with signs of inflammation, 14 had viral infections and 112 had bacterial
infection. They found that admission PCT was significantly higher in chlidren with septic
shock (94.6 ng/mL), compared with localized bacterial infection (2.9 ng/mL), viral
infection (0.8 ng/mL) and non-infected controls (0). Area under die ROC curve was
0.96 for PCT, 0.83 for CR2 and 0.51 for leukocyte count. A cutoff concentration for
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optimal prediction of sepdc shock was > 20 ng/mL for PCT and> 50 mg/L for CR2.
They suggested a procalcitonin concentration of> 2 ng/mL to be useful in
differendating severe bacterial diseases in infants and children.
Lorrot et ai)” evaluated 436 infants and children hospitalized for bacterial (162 patients)
or viral infections (274 patients) and compared PCT, CR2, intcrleukine-6 and interferon
alpha as markers for bacterial infection. A threshold for PCT of> 1 ng/mL had a
sensidvity of78% and a specfficitv of94%, while a cutoff value of> 20 mg/L for CR2
had a sensitivity of $5% and a speciflcity of 73%. They concluded that a PCT value of I
ng/mL or greater had better specificity, sensïtivity and predicuve value than CR2, IL-6 or
interferon-aipha in children for disdnguishing between bactenal and viral infections.
Muller et a1. studied 101 consecutive critically iii aduits with SIRS. Bactenal sepsis was
found in 58% of the cases versus 42% of non-infected controls. Serum PCT
concentrations were signfficantly elevated only in patients with bacterial infection (sepsis,
severe sepsis or sepuc shock). With a cutoff value of I ng/mL, PCT was found to be the
most discriminatory laboratory variable as compared with CR2, interleuldn-6, and lactate
values, with an overafi sensitivity of 89% and specificity of 94%. They also found that
high serum PCT concentrations were associated with poor prognosis.
Penel et al.’°9 evaluated PCT and CR2 as diagnostic markers in 68 consecunve non
neutropemc febrile patients with solid tumors and suspected infection. Forty-three (43)
patients were confirmed to have bactenal infection. There was no significant difference
in the CR2 levels ofboth groups (infected 134 mg/L vs. non-infected 154 mg/L.
However, PCT was signfflcandy bigher in the infected patients (0.44 ng/mL vs. 0.26
ng/mL). With a threshold of 1 ng/mL for PCT, sensiuvity was 37.2% and specificity
94.7% and with a threshold of 2 ng/mL, specfficity was 100% for die diagnosis of
infection.
Rothenburger et al)62 evaluated PCT and CR2 as diagnostic markers for bactenal
infection following cardiopulmonary bypass in a non-infected group (43 patients) and in a
bacteria-infected group (15 patients). They found PCT to be useful to differendate
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between acute phase response following cardiopulmonary bypass or local infections from
systemic infections. They found a PCT threshold of 4 ng/mL combined with a CRi’
value of 180 mg/L to represent the best cutoff points which distinguish between acute
phase response and infection. PCT sensitivity was 86% and speciflcitv 98%, while CR2
sensitivity vas 100% and specificity 75%.
Schwarz et a1) compared PCT and CRi’ levels at admission of 30 adult patients with
meningitis (16 bacterial and 14 non-bacterial). They also evaluated white blood count,
cerebrospinal fluid leukocyte count, cerebrospinal ftuid protein and lactate levels in these
two populations. They found PCT (cutoff level of 0.5 ng/mL) to be the variable with the
highest specificity for the diagnosis ofbacterial infection (100%), despite a low sensitivity
(79%). Using a CR2 cutoff value of $ mg/L, the sensitivity was 94%, but the speciflcity
was only 57%. They concluded that PCT vas a useful additional variable for
distinguishing bacterial from non-bacterial meningitis.
Selberg et al.12° prospectively evaluated PCT and CR2, together with interleukin-6,
protein complement 3a and leukocyte elastase in 22 adult patients with sepsis and 11 with
SIRS. They found that plasma concentrations of PCT, C3a, and IL-6 were signiflcandy
higher in patients with sepsis. With a threshold for PCT of 3.3 ng/mL, sensitivity was
86% and specificity 54%, while for a ±reshold of 60 mg/L for CR2 sensitivity was
but specificity was only 18%. They concluded that PCT, IL-6 and C3a were more reliable
to differentiate between sepsis and SIRS than the other markers. They recommended an
early assessment of patients with SIRS and suspected sepsis with PCT and C3a.
Suprin et al.125 prospectively assessed the use ofPCT and CR2 for the diagnosis of
bacterial infection in 77 patients with bacterial infection and 20 patients with SIRS in a
medical ICU. Initial PCT and CR2 levels were higher in infected patients compared to
patients with SIRS, regardless of the severity of sepsis. For a PCT cutoff value of 2
ng/mL, sensitivity was 65% and speciflcity 70%. For a CR2 cutoff value of 100 mg/L,
both sensitivity and speciflcity were 74%. Both serum levels ofPCT and CR2 were
signiflcandy bigher in patients with septic shock, than in those with SIRS, sepsis and
severe sepsis. CR2 levels, but not PCT, were higher in severe sepsis than SIRS. They
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concluded that PCT and CRP had poor sensitivity and specfficity for the diagnosis of
infection.
Ugarte et aL34 evaluated PCT and CR2 as markers of infection in cridcally iII patients of a
medical ICU; 111 patients with bacterial infections were compared to 79 non-infected
patients. They found the best cutoff value for PCT 0.6 ng/mL and for CR2 79 mg/L.
Compared with CR2, PCT had lower sensitivity (67.6% vs. 71.$%), specificity (61.3% vs.
66.6%), and area under the receiver operating characteristic cunre (0.66 vs. 0.7$)
respectively. They concluded that neither PCT nor CR2 was a good marker of infection
in critically ii patients. However, they could represent a useful adjunctive parameter to
idenufy bacterial infection and correlated well with severity of infection.
Viallon et ai129 assessed the role of PCT and proinflammatory cytokines (TNF-Œ and IL-
6) in the diagnosis of spontaneous bacterial peritonitis. They evaluated 21 patients with
spontaneous bacterial peritonitis and 40 patients with sterile ascitic fluid in the emergency
room. For the diagnosis of spontaneous bacterial peritonitis, the best markers were
serum levels ofPCT, with a cutoff value of 0.75 ng/mL (sensitivity 95% and specificity
9$%) and ascitic fluid levels of IL-6. CR2 had low sensitivity (62%) and specificity
(57%). They concluded that serum PCT might become a useM marker for die diagnosis
of spontaneous bacterial pentonitis in cirrhotic patients.
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I)etai/ on stîicÏies exc/ziclecÏ in t!nt meta—unatysis
Brunkherst et al.° evaluated PCT, CRP, white blood count and APACHE-II score in 185
patients with suspecteci infection (ail etiologics). They found PCT to be a good rnarker to
clifferentiate patients with sepsis anci severe sepsis, with sensibility of 96% and specificity
cf 86°/i (cutoff value of 2 ng/rnL. Data to construct the 2 by 2 tables could not be
extracteci from the papcr and wc were unable to complete them with the original author.
Gendrel et ai. evaluated PCT and CRP as markers for bacterial versus viral meningitis
in chiidren. They found PCT to lie a better marker than CRP for the diagnosis of
bacterial mcningitis. One study77 vas exciuded from die meta-analysis because the
population evaluated was a part of the populatiots in another study already included’7
and no complete data vas availabic. The other study7i vas exciuded because it was a
part of another study already included’7, with repeat data.
-Iedluncl et al.2 prospectlvely evaluateci PCT and CRP as indicators of etiology and
prognosis in patients admitted for commumty-acquired pneumoflia. They found that all
patients haci elevated CR1 levels at admission (> 10 mg/L, but only S4% had elevated
PCT levels (> t).1 ng/mL). The severlty of discase measured by APACHE II score vas
strongly associated with admission leveis ofPCT, but not CRP. This study was cxcluded
because there xvas not a control group without bacterial infection and data extraction was
flot possible.
Meisner et al.’ looked at die kinetics ofPCT and CRP in die postoperative course of
different types of surgery and compared normal with abnormal postoperative course,
inclucling infectious and other complications. This study vas excluded because study
design was not geareci towards the evaluation of the role ofPCT and CRP as diagnostic
markcrs of infection.
Moulin et al.°2 evaluatccl PCT and CRP as markers for bacterial versus viral pneitioia
in hospitahzed children. They found PCT (eut_off value of I ng/mL) to have a better
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sensitivity, specificitv and greater positive and negadve predictive values when compared
to CRP, IL-6 or white blood count. This swdy was excluded from the meta-analysis
because it evaluated a subgroup of patients and an extension of another study aiready
included47, with repeated data.
Oberhoffer et ai1’ evaluated inflammatory markers in sepdc patients as a prognostic
indicator. They found that PCT vas the better marker associated with outcome when
compared with CRi’, leukocyte count, and body temperature. This study was exciuded
because study design was flot geared towards the evaluation of the role of PCT and CRi’
as diagnostic markers of infection, and prognosis was evaluated as outcome.
Somech et al.’24 evaluated PCT and CRi’ as acute markers in febrile cbildren, but could
flot separate those patients into groups according to different etiologies of their fflness.
They found a parallel rise in PCT and CRP. The study was probably a retrospecuve
analysis of data and study design vas flot geared towards the evaluation of the foie of
PCT and CRi’ as diagnostic markers of infection.
Von Heimburg et al.’3’ evaluated the correlation between admission ieveis ofPCT with
CRP, sepsis, burn size, inhalation injury and mortality in severeiy burned patients. They
found PCT levels to correlate with severity ofinjury and septic complications. This study
was excluded because data extraction xvas not possible.
Tschaikowsky et al.’61 determined die time course of histocompatibffity leukocyte antigen
(HLA)-DR expression in penpheral blood mononuclear ceils and their relationship to
markers of inflammation, organ function, and outcome during severe sepsis. This study
excluded because study design was flot geared towards the evaluation of the role of
PCT and CRi’ as diagnostic markers of infection.
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EvaÏuating qua1iy ofthe studies
The methodology for designing and conducdng studies of diagnostic accuracy is sdil
mawring and there is an understanding that the sources ofvariabffity and the potential
bias is growing. We evaluated the methodological qualir of the included studies by
applying the criteria for assessing randomized cinical trials design-related bias described
by Chalmers et al.164 Four aspects of each smdy were evaluated for the assessment of die
quality of the research: (1) basic descriptive material; (2) study protocol; (3) analysis of the
data and (4) data potentially useful for combination of several randomized dinical trials
resuits. The latter three aspects were graded and a score was awarded to each item under
each aspect. Subsequendy, an overail quality index for each swdy was obtained by adding
up the item scores and dividing by the total possible score. Rate of agreement among the
three independent reviewers vas calculated for each item and expressed as a percentage.
In 1996 the Cochrane diagnostic and screening test methods working group updated the
“Cochrane Methods Group On Systematic Review 0f Screemng And Diagnostic Tests:
Recommended Methods.’65 In 1999 the Quality of Reporting ofMeta-analyses
(QUOROIv1) conference was convened to address standards for improving die quality of
reporting ofmeta-analyses of cinical randomised controlled trials (RCTs).166 In the same
year, at the Cochrane colloquium meeting, the Cochrane diagnostic and screening test
methods working group discussed the low methodological quality and substandard
reporting of diagnostic test evaluations. The working group felt that the first step
towards correcting these problems was to improve the quality of reporting of diagnostic
studies. The working group aimed to develop a checklist of items that should be included
in the reported of a study of diagnostic accuracy, proposing the STARD (Standardrfor
Reporting ofDiagnosticAccuray) statement to improve the quality of repornng of studies of
diagnostic accuracy.167
The STAPJD statement consists of a checklist of 25 items and flow diagram that authors
can use to ensure that ail relevant information is present. The proposed items in the
checklist are:168
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1) identify the article as study of diagnosuc accuracy (recommended MeSH heading
“sensitivity and speciflcity”)
2) state the research questions or study aims, such as estimating diagnostic accuracy
or comparing accuracy between tests or across participant groups
3) descnbe the study population: the inclusion and exclusion criteria, setting and
location where data were collected
4) describe participant recruitment: was recruitment based on presenting symptoms,
results from previous tests, or the fact that the participants had received the index
tests or the reference standard
5) describe participant sampling: vas die swdy population a consecutive series of
participants deflned by the selection critena in items 3 and 4? If not, specify how
participants were further selected
6) describe data collection: was data collection planned before the index test and
reference standard were performed (prospective study) or after (retrospective
study)
7) describe the reference standard and its rationale
8) describe techmcal specifications of material and methods involved including how
and when measurements were taken, and/or cite references for index tests and
re ference standard
9) describe definition of and rationale for the units, cutoffs and/or categones of the
results of die index tests and the reference standard
10) descnbe the number, training and expertise of the persons executing and reading
the index tests and the reference standard
11) describe whether of flot die readers of the index tests and reference standard were
blind (masked) to die results of die other test and describe any other dlinical
information available to the readers
12) descnbe methods for calculating or comparing measures of diagnostic accuracy,
and the statistical methods used to quantify uncertainty (e.g., 95% confidence
interval)
13) describe methods for calculating test reproducibffity, if done
14) report when study was done, induding beginning and ending dates ofrecruitment
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15) report clinical and demographic characteristics of the study population (e.g., age,
sex, spectrum of presenting symptoms, co-morbidity, current treatments,
recruament centers)
16) report the number of participants sadsfying the criteria for inclusion that did or
did not undergo the index tests and/or the reference standard; describe why
participants failed to receive either test (a ftow diagram is strongly recommended)
17) report time interval from the index tests to the reference standard, and any
treatment administered between them
18) report distribution of severity of disease (define criteria) in those with the target
condition; other diagnoses in participants without the target condition
19) report a cross tabulation of the results of the index tests (including indeterminate
and missing results) by the results of the reference standard; for condnuous
resuits report the distribution of the test resuits by the resuits of the reference
standard
20) report any adverse events from performing the index tests or the reference
standard
21) report esumates of diagnostic accuracy and measures of statistical uncertainty (e.g,
95% confidence interval)
22) report how indeterminate resuits, missing responses and outhers of the index tests
were handled
23) report estimates ofvariabffity of diagnostic accuracy between subgroups of
participants, readers or centers, if done
24) report estimates of test reproducibffity, if done
25) discuss the dinical applicabffity of the study findings
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Possibte bias and vaÏidi’y ofthis meta-anaysis
The present study employed a comprehensive search strategy. Formai critena for swdy
inclusion were defined prior to analysis of the search results. We were unable to find
previous attempts to summarize the accuracy of simultaneous PCT and CRP for
diagnosis of bacterial infection in the medical literawre. Our results spanned three
decades of diagnostic test evaluation. It is possible that there is an effect of time which
resuits and accuracy change according to publication urne. However, ail included studies
date from 1999 to 2001.
The present smdy attempted to summarize data from primary sources in the published
medical literature on the diagnostic accuracy of procalcitomn and c-reactive protein for
the diagnosis of bacterial infection. The studies identifled represent a rather large
population, including neonates, children and aduits. The underlying population varied,
including neonates with late sepsis, chiidren hospitalized with febrile ifinesses, cridcally ifi
children with medical ifinesses, adults hospitalized with meningitis, spontaneous bacterial
peritonitis, neutropemc febrile episodes in patients with solid tumors, criticaily ifi aduits
with medical diseases or post operatory of cardiac heart surgery. Tbis heterogeneity was
not controlled for, since we evaluated die use of these tests as markers for bacterial
infection in general. Because few studies had die same group population, a subgroup
analysis was flot performed since the smail number of studies available conferred low
power to detect such differences in accuracy.
Data were insufficient to examine other study characteristics that may have inftuenced
study outcome, such as age of participants (pediatric vs. adult), baseline disease (medical
vs. surgical or acute vs. chronic), hospital setting (wards vs. intensive care), or symptom
duration. Lag-tirne between initiation of symptoms and diagnostic strategies were flot
reported in the studies. Bacterial infection, though, is usually a progressive disease that
evolves with tirne, depending on die immune status of the patient. Therefore, unless
there is a known event diat might have initiated the infection (a certain procedure), this is
not a variabffity that can be accounted for in dinical studies. Increases in duration of
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fflness may bias studies towards bigher prevalence of proved bacterial infection. Previous
treatments may also induce a bias, smce they might change the spectrum of the disease.
There might have been some variation in the Urne of diagnositc tests (PCT and CRP) and
reference tests (cultures) performance in the studies included in this meta-analysis that
could affect results, since flot ail studies reported the exact time interval between
performance of these tests.
We must underline some strengths of dis systemadc review. Decisions on every step,
from inclusion or exclusion to data extraction were based on consensus of three
independent reviewers, giving more credibility to the resuits. There vas a high agreement
rate among reviewers in every step of this meta-analysis. Authors from individual papers
were contacted and asked to confirm or correct the information retained from the
original paper. The response rate from de contacting authors was notably high (66.7%),
giving additional strength to the data analyzed.
This study has several limitations. Firsdy, a question remains on the choice of diagnostic
reference standard. Diagnosis of bacterial infection is flot always evident; cultures are the
main reference test, but they are not aiways positive. Methods to overcome this
limitation include examining multiple data for the diagnosis of infection, such as presence
of pus or bacteria per gram stain, and combining cinical and laboratorial diagnosis of
bactenal infections, such as meningitis or osteomielitis. This remains an area for
improvement in future studies, and consensus on standardization. Most of the studies
had what were considered adequate diagnostic assessment for the reference disease status.
Misclassification of classification by an imperfect reference test wiil lead to bias in the
assessment of a diagnostic test. In general, an imperfect reference test wiil underestimate
the performance of a diagnostic test. Meta-analytic methods have been described to
adjust for imperfections in the reference standard, although those techniques were not
applied to the data presented here.16°
R is likely that other types of bias were present in some of these studies. Empincal
observation of the quantitative effects of study design fiaws on the findings of diagnostic
studies has shown dat case-control designs, studies that use different reference tests for
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positive and negative resuits of the diagnostic test under swdy, and lack of blinding led to
overestimation of diagnostic test accuracy.49 Ail included studies were case-control,
prospectively designed. Haif of the studies recruited their patients consecutively, with
minimal withdrawal from the swdy, thereby minimizing selection bias. Few studies
reported information on blinding, which could potentially have altered the
trustworthiness of the data.
Qualitv assessment of the studies was performed, but flot included in the analysis. h is
possible that difference in accuracy would have been observed ir this vas accounted for.
Several other forms of bias have flot been shown to be important predictors of variation
in assessment of diagnostic accuracy.49 Verification bias refers to the bias that may occur
if the reference test is applied based on the resuits of the diagnostic test being swdied.
None of die studies included die PCT of CRP for the diagnosis of bacterial infection or
evaluated their resuits for the decision of performing the reference tests (cultures).
Consequendy, no evaluation ofverification bias was used in tins meta-analysis.
The accuracv of diagnostic markers can depend on the specific methods used for their
measurement. Invariably, PCT measurements were performed using the commercially
available antibody system (BRAHMS, Hennigsdorf, Germany). Tins assay is specific and
uses two antibodies that bind to two sites (calcitonin and katacalcin) of the procalcitonin
molecule thus ruling out cross-reactivity. The reported detecuon limit of the assay is 0.1
ng/ml while procalcitonin levels of healthy subjects are usuaily undetectable.88 However,
methods of measurement of CR2 largely varied among the 12 included studies; 8
different methods were used for the CRP quantification. The implications of tins
variability are unknown to the final resuit of tins meta-analysis. However, each studv was
included using its own best cutoff value and the linear regression methods used in the
analysis account for possible threshold differences between studies.
h should also be noted that an apparent threshold effect can arise through variation in
other factors winch simultaneously increase (or decrease) both true positive and false
positive diagnosis rate.1
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This meta-analysis does flot evaluate serial measurements ofPCT or CRI? for the
diagnosis of bacterial infection; it evaluates a one-time measurement at the dme infection
was suspected.
Tests for heterogeneity and correlation were not performed in this meta-analysis, since
they have low statistical power when the studies in the systematic reviews have smafl
sample sizes,48 and therefore a threshold related effect may exist but remain undetected
by the statistical tests.
The main problems of meta-analysis actually arise before the analysis of the data is begun,
in the searching for studies. There is an inevitable publication bias, which is the
phenomenon by which significant and positive resuits are more likely w be reported, and
reported more prominendy, than non-significant and negadve ones. Another important
step is the selection of the studies to be included in the meta-analysis, so that they
evaluate the same outcome measurement. Despite extensive and rigorous techniques
applied during the preparanon of this meta-analysis, it is ont completely free of biases.
In the meta-analysis technique, pooling of resuits across studies or averaging sensitivity
and specificity (which are in effect the same method) causes underestimation of test
performance, because the relationship between sensinvity and speciflcity is not linear.
This is most easily understood by considering a ROC graph with two points: one at 5O%
sensitivity and 90% speciflcity and the other with 90% sensitivity and 50% speciflcity.
Averaging these resuits (or pooling if one assumes both studies have equal numbers of
positive findings) would yield a sensitivity of 70% and a specificity of 70%. Assuming a
constant diagnostic odds ratio, the tme sensitivity and speciflcity at the point where the
two are equal should be 75%. Meta-analysis of diagnostic odds ratios fails to capture the
interdependence of sensinvity and specificity.53
The logistic regression method (Uttenberg-Moses method) used in this meta-analysis
systematicafly underestimates the sensitivity and specificity for very high levels of test
performance, but the underestimation is no more than 2% for each parameter. An
increase in the size of the ducal trials bemg meta-analyzed virtually eliminates this bias.
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Back-transforming the CI from the linear regression of the logistic gives a reasonabi
conservative CI on the summary ROC curve. This too is subject to the systematic
underestimadon at very high levels of sensitivity and specificity in the meta-analysis of
small studies.53
The resuits of this meta-analysis suggest that the accuracy for PCT is higher than that of
CRP for differentiating berween bacterial and both viral infections and other non
infecdve causes of inflammation. We tried to evaluate if andbiodc administration
influenced the resuits, but there was flot enough data descriptions in the original studies
to aflow such analysis.
We selected a random effects model, that assumes that the studies included in the meta
analysis belong to a random sample of a universe of such studies, since both within-study
sampling error (variance) and between-studies variation are included in the assessment of
the uncertain (confidence interval) of the resuits of a meta-analysis. If there is
significant heterogeneity among the resuits of the included studies, random effects
models wifl give wider confidence intervals than fixed effect models. We believe that the
resuits of this meta-analysis could be generalized to different patient populations (external
validity).
This meta-analysis does not address the question of the best threshold of the tests
studied. Raw data from each individual patient would be required, which unformnately
was not available. Moreover, the sensitivity and specificity for combined tests, PCT and
CRP, could also flot be evaluated without individual raw data for PCT and CRP for every
patient included in this meta-analysis.
This study may have implications for how cinicians perform their cinical evaluation for
bacterial infections. These data show that PCT, rather than CRP, is a promising marker
for bacterial infection in hospitalized patients, with bigh sensitivity and specificitv for
differentiating between bactenal and viral infections and between bacterial infections and
non-infective causes of inflammation. h is however important to consider that these
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markers do flot allow a final diagnosis of infection, but are should rather view as
screening tool in dinical practice.
This study lias imphcanons for cinical research. This swdy has highlighted the selected
nature of existing data on diagnostic accuracy of simultaneous PCT and CRP for the
diagnosis ofbacterial infections. A potentially useful consideration would be the gain in
sensitlvity and specificity that might result from using a combination of CRP and PCT.
Further attention should be devoted to evaluating the usefulness of these tests in the
dinical practice.
$6
Future directions
The evaluation of the diagnostic accuracy of a test is also only one component of
assessing whether it is of cinical value. Therapeutic interventions can only be
recommended for use in health care only if they are shown on average to be of benefit to
patients: the same criteria apply for the use of a diagnostic test, and even the most
accurate of tests can be dinically useless and do more harm than good. Studies of
diagnostic accuracy cannot prove that a diagnostic investigation is effective, but can
discern whether the performance of a test is satisfactory for it to have the potential to be
effective.48
In order to answer some of these questions, we designed a prospective piot-swdy of
consecutive cases of SIRS in the Pediatric Critical Care Unit of Sainte-Justine Hospital.
The objectives were to determine the feasibility of a multicenter study in order to
determine the predictive value ofPCT as a diagnostic marker for bactenal infections in
criticafly iii children with SIRS. Secondary objectives would be to determine the
predictive value of PCT combined with CRP as diagnostic markers for bacteriai
infections; to determine the influence of prior use of andbiotics on the predictive value of
these tests; to estimate the accmal of information provided by PCT with respect to the
diagnosis of bacterial infection in critically di chiidren with SIRS in comparison to the
value of other tests (cinical data, Gram coloration, CRP, etc); to compare the a priori
probabffity (pre-test odds) of infection, as estimated by clinician at the bedside, to the a
posteriori probabffity (revised probabffity, or post-test odds), as esumated by the same
dinician, given the new information provided by PCT, dinical data, Gram coloration,
CRP, etc.; to estirnate and to compare the cost-usefulness of these tests: PCI and CRP in
terms of changes in the ducal practice, decreasing antibiotic days, decreasing admission
time in the PICU and/or mortality.
We screened 259 patients with SIRS over a 7-month period and included 66 patients,
collecring baseline data, PCT, CRP, and diagnostic tests for infection (blood and urine
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cultures and ETT and/or other cultures deemed relevant). This swdv is currently in the
phase of data analysis.
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Conclusion and Retvrnmendation
\Vith this meta-analysis, we can conclude that the overail accuracy of PCT is higher than
that of CRP for differentiating between bacterial and both viral infections and other non
infective causes of inflammation in hospitahzed patients.
At this point, PCT should be favored over CRI’ for the use in cinical practice as an early
diagnostic marker for bacterial infection in hospitalized patients. The remaining
questions are the combined accuracy of PCT and CRP and the cinical utility of these
tests. These answers should be provided with the planned multicenter study.
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Annexes
Annex I: abstractforpresentation al the “Congrès des Résidents du
Département de Pédiatrie “, November 2002, Hopitat Sainte-Justine, Universiy of
Montreal f2C, Canada
Procalcitonin and C-Reactive Protein as markers of bacterial infection:
a meta-analysis
Lifiana Simon, france Gauvin, Devendra Amre, Chantai Roy, Patrick Saint-Louis, Jacques
Lacroix, Hôpital Sainte-Justine, Université of Montréal, Quebec, Canada
Introduction: Bacterial infections are a major cause for SIRS (Systemic Inflammatory
Response Syndrome) that is frequendy associated with hospitalization, death, and
substantially increases costs related to health care. Differendation of bacterial infection
(sepsis) as a cause for SIRS from viral and other non-infective causes is important for the
appropnate use of antibiotics. However, on many occasions, presendy used culwre
methods delay diagnosis and result in over usage of anubiotics. The latter is primarily
responsible for the development of multi-resistant bactena hampering effective
management. Semm biomarkers such as Procalcitonin (PCI) and C-reactive protein
(CRP) have been suggested as early diagnostic markers of bacterial infection. However,
their accuracy and dlinical utility remains unknown.
Objective: We conducted a meta-analysis of published studies to compare die accuracy
of serum PCT and CRP as diagnostic markers of bacterial infection.
Data Sources: Ail studies published in Medline from January 1, 1970 through May 30,
2002 that evaluated PCT and/or CRP for the diagnosis of bacterial infections were
identifled using pre-established search strategies and considered for analysis. Cross
references, computer databases and published books were also reviewed to idendfy
relevant studies.
Study Selection: Prospective studies carried out among hospitalized patients were
evaluated. No restriction was placed on die age group of the population studied.
Retrospective studies, reviews and studies with incomplete data were excluded. Relevant
articles were selected by three independent reviewers. Discrepancies or disagreements, if
any, on the inclusion or exclusion of studies were resolved by consensus.
Data Extraction: The data was extracted in 2 by 2 tables. Authors of individual articles
were contacted to complete/correct any missing/incorrect information.
Data Analysis: 22 articles were selected for revision and 14 were included (1355 patients)
in the meta-analysis. Data were summarized using linear regression methods that account
for possible threshold differences between studies and SROC (Summary Receiver
Operating Charactenstic) curves were generated to compare the accuracy of the
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diagnostic tests. for differentiating between bacterial and non-infective causes of
inflammation, PCT was more sensitive (Se) than CRP: 0.86 [95% CI 0.75 — 0.91] versus
0.71 [95% CI 0.63 — 0.79]. PCT also had a higher Specificity (Sp) than CRP: 0.80 [95%
CI 0.65 — 0.90] versus 0.71 (95% CI 0.62-0.79). This was also reflected in the higher Q
value obsewed for PCT: 0.81 and 0.73 respectivelv. When differentiating between
bacterial and viral infections, the Se for PCT vas better than CRP (0.9 1 [95% CI 0.85 —
0.95] versus 0.82 [95% CI 0.74 — 0.88]), the Sp were however comparable (0.82 [95% CI
0.74 — 0.88] versus 0.86 [95% CI 0.76 — 0.93]). The overail accuracy was also higher for
PCT: Q values 0.88 and 0.78 respectivelv.
Conclusion: The overail accuracy of PCT is higher than that of CRP both for
differendating berween bacterial and viral infections and bacterial and other non-infecdve
causes of inflammation. The cinical utili and the cost-benefit aspects of this test need
to further evaluated.
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Annex II: abstrat’tfor oralpresentation at the ‘1th World Coigress on
Pediatric Intensive Care “, June 8 - 12, 2002 - Boston, I’L4, USA
Serum Procalcitonin (PCT) and C-Reactive Protein (CRP) as markers of
bacterial infection: a meta-analysis
LiÏiana Simon, france Gauvin, Devendra Amre, Chantai Roy, Patrick Saint-Louis,
Jacques Lacroix
Objective: Differentiation between bacterial, virai and non-infective causes of
inflammation is important for the appropriate management of affected patients. A
meta-analysis companng the accuracy of serum PCI and CRP for the diagnosis
bacterial infection was performed.
Methods: A Mediine search between January 1, 1970 and May 30, 2002 for
identifying articles evaluating PCI andlor CRP for the diagnosis ofbacterial
infections was performed. Prospective studies among hospitaiized patients were
seiected. Each article was independently reviewed by three reviewers and data
extracted in 2x2 tables. Discrepancies/disagreements were resoived by consensus.
Authors of individuai articles were contacted to complete/correct any
missing/incorrect information.
Resuits: A total of 12 articles were retained in the final analysis (1499 patients). Data
were summarized by estimating pooled accuracy measures and SROC (Summary
Receiver Operating Characteristic) curves were generated. For differentiating
between bacteriai and non-infective causes of inflammation, PCI was more sensitive
(Se) than CRP: 0.87 [95% CI 0.79 — 0.92] versus 0.72 [95% CI 0.62 — 0.80] and more
specific (Sp) 0.83 [95% CI 0.68 — 0.92] versus 0.76 [95% CI 0.63-0.85] respectively.
Overaii accuracy, measured by the Q-value, was aiso higher for PCI: 0.83 versus 0.75
respectiveiy. When differentiating between bacteriai and viral infections, the Se for
PCI was higher than CRP (0.90 [95% CI 0.86 — 0.93] versus 0.62 [95% CI 0.51 —
0.72]), but the Sp was lower (0.76 [95% CI 0.52 — 0.90] versus 0.94 [95% CI 0.78 —
0.98]). Q values were higher for PCI: 0.88 and 0.73 respectively.
Conclusion: Ihe overail accuracy of PCI is higher than that of CRP both for
differentiating between bacterial and viral or non-infective causes of inflammation.
PCI couid be recommended for widespread use in clinical practice.
Annex III: BookÏetfor data extraction
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DIAGNOSTIC DES INFECTIONS PAR LA
PROCALCITONINE (PCI) OU LA C-REACIIVE PROTEIN
(CRP) CHEZ DES PATIENTS TRAITÉS EN SOINS
INTENSIFS: MÉTA-ANALYSE.
Livret d’annotatïon
Last update: March 22, 2002 vv.
A) Données générales
1. Nom de l’examinateur
1.1. Liliana Simon (noter le chiffre 1)
1.2. Lars Desmets (noter le chiffre 2)
1.3. Guillaume Emeriaud (noter le chiffre 3)
1.4. Soraya Cinthia Mendes Xavier (noter le chiffre 4)
2. Description bibliographique de l’article évalué:
2.1. Nom du premier auteur
2.2. Nom de la revue
2.3. Année de publication 19 ou 200
2.4. Volume de la revue
2.5. Pages de l’article
3. Critères d’inclusion (tous les critères doivent être présents) oui non
3.1. Article ou abstract publié après revue par des pairs O O
3.2. Etude prospective O O
3.3. Etude portant sur des patients hospitalisés ou vus en salle d’urgence O O
3.4. Etude portant sur la procalcitonine (PCT) O O
3.5. Etude portant sur la protéine C réactive (CRP) O O
3.6. Etude cherchant à identifier une infection O O
4. Causes d’exclusion a priori de la méta-analyse valables pour toutes les études (NB: un
seul critère suffit pour exclure une étude, mais nous vous demandons de cocher tous
les raisons d’exclusion de cet article): oui non
4.1. Etude confondant les infections avec d’autres pathologies O O
4.2. Etude sans groupe-contrôle O O
4.3. Etude incluant des patients non-hospitalisés O O
4.4. Etude ne portant ni sur la PCI ni sur la CRP O O
4.5. Etude ne comportant pas au moins l’un des tests de la question 8 O O
4.6. Etude ininterprétable O O
4.7. Etude faite chez l’animal O O
4.8. Etude rétrospective O O
4.9. Etude non publiée O O
4.10. Etude publiée après le premier avril 2002 O O
4.11. Etude publiée avant le premier janvier 1970 O O
4.12. Etude introuvable O O
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4.13. Étude répétant des données publiées ailleurs . O O
4.14. Editorial, revue, mise à jour, chapitre de livre O O
4.15. Thèse non publiée dans une revue avec comité de lecture O O
4.16. Autre Qréciser ) O O
5. Cause d’exclusion a posteriori de la méta-analyse d’une étude, c’est-à-dire exclusion
après analyse des résultats par les 3 experts (N.B.: cette question sera répondue par
Jacques Lacroix): oui non
5.1. Données non fournies ni par l’article ni par l’auteur O O
5.2. Impossibilité d’obtenir un consensus des experts O O
5.3. Autre (préciser ) O O
6. Causes d’exclusion a priori de la partie de la méta-analyse portant sur les données
stratifiées selon que le patient recevait ou non des antibiotiques au moment du
prélèvement des tests (PCT, CRP, etc.) (NB: un seul critère suffit pour exclure l’étude
de cette partie de la méta-analyse, mais nous vous demandons de cocher tous les
raisons d’exclusion de cet article): oui non
6.1. Données non fournies ni par l’article ni par l’auteur O O
6.2. Autre (préciser ) O O
7. Etude publiée sous la forme oui non
7.1. d’un résumé (abstract) O O
7.2. d’un article O O
7.3. autre type de publication (ex. thèse) O O
2. Description de l’étalon de référence (gold standard) de l’étude. — Les auteurs ont
diagnostiqué les infections en se basant sur le ou les critères suivants (cocher toutes
les bonnes réponses): oui non
8.1.Onclinicaldata O O
8.2.Onradiologicaldata O O
8.3. On sample ofupper respiratory secretions (trachea) O O
8.4. On sample oflower respiratory secretions (brnsh, BAL, etc) O O
8.5.Onbloodculture O O
8.6. On urine culture O O
8.7. On culture of spinal fluid O O
8.8. On culture of skin O O
$.9.Onabiopsy O O
8.10. On an autopsy O O
8.11. On culture for bacteria O O
8.12. On culture for fungi O O
8.13. On culture for virus O O
8.14. On an increase ofantibody titer O O
8.15. On serological identification of germ(s) (i.e. ELISA) O O
8.16. On biochemical identification ofgerm(s) (i.e. PCR) O O
8.17. On other criteria O O
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B) Évaluation des études cliniques 1
B. I Données de bases (basic descriptive material): dans cette
section, II faut cocher une seule bonne réponse par question.
1. Biostatisticien: oui
1.1. Un biostatisticien fait partie des auteurs O
1.2. L’aide d’un biostatisticien est signalée dans les remerciements O
1.3. Ni l’un, ni l’autre O
1.4. Donnée inconnue O
2. Pays d’origine du projet de recherche (country): oui
2.1.Etats-Unis O
2.2. Royaumes-Unis O
2.3. Pays scandinaves O
2.4. Autre pays (spécifier ) O
2.5. Donnée inconnue O
3. Centre(s) hospitalier(s) (center status): oui
3.1. Un seul centre hospitalier O
3.2. Multicentrique, mais moins de 5 centres O
3.3. Multicentrique, et 5 centres O
4. Sources de financement; cocher toutes les réponses positives (sources of financial
support; multiple items possible): oui
4.1. N.I.H. ou C.I.H.R O
4.2. Autre organisme subventionnaire pourvu d’un comité de révision O
4.3. Autre organisme subventionnaire sans comité de révision O
4.4. Compagnie pharmaceutique O
4.5. Autre source (spécifier ) O
4.6. Aucune source de financement précisée O
5. Provenance des patients; cocher toutes les réponses positives (sources of patients;
multiple items possible): oui
5.1. Hôpital universitaire O
5.2. Hôpital public O
5.3. Hôpital privé O
5.4. Clinique non hospitalière O
5.5. Industrie O
5.6. Autre source (spécifier ) O
5.7. Aucune source précisée O
6. Signification des résultats (significance of findings; cocher un choix): oui
6.1. Résultat statistiquement significatif et en faveur du groupe étudié
(-H-; statistically significant treatment or result) O
6.2. Tendance positive (positive trend in favor of treatment or test) ... O
La liste de questions inclues dans la section B est inspirée fortement de l’article suivant:
Chalmers TC, Smith H, Blackbum B, et al. A method of assessing the quality of a
randomized control trial. Controlled Clin Trials 1981;2:31-49.
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6.3. Pas de différence (no difference) O
6.4. Tendance négative (trend in favor of control) O
6.5. Résultat statistiquement significatif, mais en faveur du groupe contrôle
(statistically significant control) O
6.6. Opininion de l’auteur très en faveur ou très en défaveur du traitement ou du test
étudié, mais aucune statistique proposée O
6.7. Statistique non faite O
7. Effet secondaire du traitement ou du test (side effect; ex. pneumothorax): oui
7.1. Incidence statistiquement significative (statistically significant treatment or
resuit) O
7.2. Tendance positive (positive trend in favor oftreatment or test) O
7.3. Pas d’effets secondaires (no side effects) O
7.4. Données manquantes O
8. Type d’étude; cocher toutes les réponses positives (type of trial; multiple items
possible): oui non
8.1. Comparaison simple (simple comparative) O O
8.2. Avec blocs (restricted; blocking) O O
8.3. Stratifiée (stratified) O O
8.4. En chassé-croisé (cross-over) O O
8.5. factorielle (factorial) O O
2.6. Autre type (spécifier ) O O
8.7. Type inconnu ou imprécisable O O
B2 Évaluation du plan de l’étude d’un test (evaluation of the
design in the study protocol): dans cette section, II faut annoter
le pointage approprié pour chaque question.
9. Description de la méthode de collectage des patients (description ofthe method used to
collect patients): points
> Description adéquate (adequate) : 3 points
>Description acceptable (fair): 1.5 points
Description inadéquate (inadequate)) : O point
10. Description du nombre de patients vus et exclus (number of patients seen and rej ect
log): points
Description détaillée: 3 points
Description partielle: 1.5 points
Aucune description, donnée manquante (unknown)) : O point
11. Attrition, c’est-à-dire retrait en cours d’étude (withdrawals): points
> Description détaillée (list given) : 3 points
Pas d’attrition: 1.5 points
Aucune liste, donnée manquante (unknown) ou taux de retraits> 15 % pour une
étude à long terme ou> 10 % pour une étude ayant duré moins de 3 mois: O point
12. Description du test étudié (test definition): points
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Description adéquate (adequate) : 3 points
> Description acceptable (fair) : 1.5 points
> Description inadéquate (inadequate) : O point
13. Test servant d’étalon de référence (gold standard used):
13.1. Description de l’étalon de référence: points
L’étalon de référence est précisée de façon adéquate: 3 points
L’étalon de référence est précisée de façon acceptable: 1.5 points
L’étalon de référence est précisée de façon inadéquate ou il n’est pas précisée
(unstated) : O point
13.2. Valeur de l’étalon de référence choisi: points
L’étalon de référence est adéquat: 10 points
L’étalon de référence est acceptable: 5 points
L’étalon de référence est inadéquat: O point
14. L’échantillon a été collecté chez des cas consécutifs: points
Oui: 3 points
Non: O point
> Donnée manquante (unknown) : O point
15. Tous les tests ont été faits chez tous les patients inclus dans l’étude: points
>Oui: 3 points
Non: 1.5 points
Donnée manquante (unknown) : O point
16. Les tests ont été prélevés sans que la condition du patient ne soit connue par la
personne faisant le prélèvement: points
Oui: 3 points
Partiellement: 1.5 points
Non ou donnée manquante (unknown) : O point
17. Les analyses paracliniques des prélèvements ont été réalisées sans que la condition du
patient ne soit connue par la personne faisant l’analyse en laboratoire points
Oui: $ points
Partiellement: 4 points
>Non ou donnée manquante (unknown) : O point
1$. Le nombre de patients nécessaires pour réaliser l’étude a été évalué avant que l’étude
ne soit commencée (prior estimate ofnumbers: endpoints selected, difference of
clinical interest cx and 13 estimated): points
>Oui: 3 points
Non ou donnée manquante (unknown) : O point
a) Total du pointage pour la section B.2: points
b) Total maximum possible du pointage pour la section B.2: 45 points
Proportiona/b(%): %
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B..3 Analyse statistique : dans cette section, il faut annoter le
chiffre de la bonne réponse pour chaque question.
20.3.
20.4.
19. Évaluation de l’objectif primaire, soit le diagnostic d’infection: points
Le test statistique employé est décrit et les résultats du calcul statistique (p, odds
ratio avec son intervalle de confiance à 95 %...) sont précisés: 4 points
Le test statistique fait n’est pas précisé, mais les résultats obtenus le sont: 1 point
> Le test statistique fait est précisé, mais pas les résultats obtenus: 1 point
Ni le test statistique, ni les résultats obtenus ne sont précisés: O point
20. Inférence statistique
20.1. Intervalle de confiance: points
Oui: 3 points
> Non: O point
Donnée inappropriée ou donnée manquante (not available) : O point
20.2. Régression ou corrélation entre les tests calculée: points
Oui: 2 points
Non: O point
Donnée inappropriée ou donnée manquante (not available) : O point
Taux de concordance évalué et rapporté: points
Oui: 2 points
Non: O point
Donnée inappropriée ou donnée manquante (not available) : O point
Score de kappa évalué et rapporté: points
Oui: 2 points
Non: O point
Donnée inappropriée ou donnée manquante (not available) : O point
21. Reproductibilité du test (reproducibility of the test) 2 points
Reproductibilité évaluée: 4 points
Reproductibilité non évaluée: O point
22. Validité du test (accuracy ofthe test)
22.1. Sensibilité, spécificité: points
Sensibilité et spécificité du test évaluées: 4 points
Sensibilité ou spécificité du test évaluée: 2 points
Ni sensibilité ni spécificité évaluée: O point
22.2. Courbe receiver oparating characteristic (ROC): points
Courbe ROC construite: 4 points
Pas de courbe ROC: O point
23. Les tests statistiques choisis sont-ils appropriés?
23.1. Les tests statistiques choisis sont-ils appropriés? points
Tout à fait (excellent) : 4 points
> Plus ou moins (good) : 2 points
2 Cette question est inspirée de l’article suivant: Cook DJ, Fitzgerald JM, Guyatt GH,
Walter S. Evaluation of the protected brush catheter and bronchoalveolar lavage in the
diagnosis of nosocomial pneumonia. J Intensive Care Med 1991 ;6:196-205.
Cette question est de notre propre cru.
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Pas tellement (fair) : 1 point
Pas du tout (poor) : O point
23.2. L’analyse statistique est-elle bien faite? points
Tout à fait (excellent) : 4 points
Bonne (good) : 2 points
Assez bonne (fair): 1 point
Pas du tout (poor): O point
24. Retraits pendant l’étude (withdrawals).
24.1. Description des retraits dans l’article (description of withdrawals) points
Pertes décrites d’une façon ou l’autre (listed) : 4 points
> Aucun retrait (none) : 4 points
> Pas de description des retraits ou donnée inconnue (no list/unknown) : O point
Taux de retraits> 15 %: O point
24.2. Conduite face aux retraits (handling ofwithdrawals). points
Pertes analysées d’une façon ou l’autre (analyzed several ways) : 4 points
> Inclus dans la randomization (included in original randomization) : 4 points
Cas exclus (discarded): 1 point
Le cas est changé de groupe (changed groups) : O point
Conduite inconnue (unknown), pas d’attrition ou donnée non disponible (no
withdrawal/N.A.): O point
25. Discussion concernant les complications ou les coûts associées au test étudié (side
effects discussion). points
Adéquate: 3 points
Correcte (fair): 1.5 points
Insatisfaisante (poor) ou non disponible (N.A.) : O point
26. L’analyste ou le statisticien ont calculé les statistiques sans connaître les résultats
attendus (blinding of statistician or analyst to expected resuits) points
Oui: $ points
> Partiellement: 4 points
Non ou donnée manquante (unknown) : O point
a) Total du pointage pour la section B.3: points
b) Total maximum possible du pointage pour la section B.3: 44 points
Proportiona/b(%): %
B.4 Présentation des résultats (presentation of resuits): dans
cette section, II faut annoter le chiffre de la bonne réponse.
27. Les dates du début et de la fin de l’étude sont précisées (dates of starting and stopping
accession): points
>Oui :2 points
Non: O point
28. Résultats avant la randomisation (results of prerandomization); c’est-à-dire analyse
des données de base obtenues (baseline data): points
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Analyse des résultats (data analysis) adéquate: 2 points
Analyse des résultats (data analysis) acceptable (fair) : 1 point
Analyse des résultats (data analysis) inadéquate ou donnée manquante: O point
29. Le temps d’apparition des événements est précisé (timing of events) points
De façon adéquate (adequate) $ 4 points
De façon acceptable (fair) : 2 points
De façon inadéquate (inadequate) : O point
a) Total du pointage pour la section B.4: points
b) Total maximum possible du pointage pour la section 3.4: 8 points
Proportion a / b (%): %
a) Total du pointage des sections 3.2, 3.3 et 3.4: points
b) Total maximum possible du pointage des sections 3.2, 3.3 et 3.4: 97 points
Proportion a /b (¾): %
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C) Extraction des données (annotation des résultats de
l’étude)
C. I Procalcitonine (PC T)
30. Cette étude évaluait la valeur de la PCT pour le diagnostic d’une infection:
Oui
Non
N.B.: ne pas remplir le reste de la section C. 1 si vous avez répondu par la négative à
la question précédente.
31. Dans cette étude, la PCT était mesurée par laquelle ou lesquelles des méthodes
suivantes (cocher toutes les bonnes réponses)?
Immuno-luminometric assay ( LUMItest®PCT, BRAHMS Diagnostica (Berlin,
Germany).
Semi-quantitative test (PCT-Q, BRAHMS Diagnostica, Berlin, Germany).
Autre méthode:
32. Dans cette étude, quel était le seuil de PCI considéré comme limite supérieure de la
norme? Procalcitonine (PCI):
________
ng/mL.
33. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la PCI étaient les suivantes pour l’ensemble des patients (s’il-vous-plaît,
n’écrivez rien dans la table de contingence à droite):
Test
PCT+
PCT
GOLD STANDARD
Infection No infection
TP: FP:
FN: IN:
DATA IN PAPER
GOLD STANDARD
Sepsis No fection
CORRECTION
34. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la PCT étaient les suivantes pour les patients ayant reçu au moins une
Méta-analyse, livret, PCI et CRP
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dose d’antibiotique au cours des 24 heures précédant le prélèvement sanguin pour la
mesure de la PCT (s’il-vous-plaît, n’écrivez rien dans la table de contingence à droite):
Test
PCT+
PCI-
GOLD STANDARD
Infection No infection
IP: FP:
FN: TN:
DATA IN PAPER
GOLD STANDARD
Sepsis No infection
CORRECTION
35. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la PCT était les suivantes pour les patients n ‘ayant pas reçu au moins
une dose d’antibiotique ail cours des 24 heures précédant le prélèvement sanguin
pour la mesure de la PCI (s’il-vous-plaît, n’écrivez rien dans la table de contingence à
droite):
Test
PCI+
PCT
GOLD STANDARD
Infection No infection
TP: FP:
EN: IN:
DATA IN PAPER
GOLD STANDARD
Sepsis No infection
CORRECTION
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C.2 Protéine C réactive (CRP)
36. Cette étude évaluait la valeur de la CRP pour le diagnostic d’une infection:
u Oui
u Non
ne pas remplir le reste de la section C.2 si vous avez répondu par la négative à
la question précédente.
37. Dans cette étude, quel était le seuil de CRP considéré comme limite supérieure de la
norme? C reactive protein (CRP):
________
ng/mL or________
3$. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la CRP étaient les suivantes pour l’ensemble des patients (s’il-vous-plaît,
n’écrivez rien dans la table de contingence à droite):
Test
CRP+
CRP
GOLD STANDARD
Infection No infection
TP: FP:
FN: TN:
DATA IN PAPER
GOLD STANDARD
Sepsis No infection
CORRECTION
39. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la CRP étaient les suivantes pour les patients ayant reçu au moins une
dose d’antibiotique au cours des 24 heures précédant le prélèvement sanguin pour la
mesure de la CRP (s’il-vous-plaît, n’écrivez rien dans la table de contingence à
droite):
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CRP+
Test
CRP
GOLD STANDARD
Infection No infection
TP: FP:
FN: TN:
DATA IN PAPER
GOLD STANDARD
Sepsis No infection
CORRECTION
40. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la étaient les suivantes pour les patients n ‘ayant pas reçu au
moins une dose d’antibiotique au cours des 24 heures précédant le prélèvement
sanguin pour la mesure de la (s’il-vous-plaît, n’écrivez rien dans la table
de contingence à droite):
Test
CRP+
CRP
GOLD STANDARD
Infection No infection
TP: FP:
EN: TN:
DATA IN PAPER
GOLD STANDARD
Sepsis No infection
CORRECTION
Méta-analyse, livret, PCT et CRP
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C.3 Autre test
41. Cette étude évaluait la valeur de pour le diagnostic d’une infection:
Oui
Non
N.B.: ne pas remplir le reste de la section C.3 si vous avez répondu par la négative à
la question précédente.
42. Dans cette étude, quel était le seuil de considéré conune limite
supérieure de la norme?
_________________________
43. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la étaient les suivantes pour l’ensemble des patients (s’il
vous-plaît, n’écrivez rien dans la table de contingence à droite):
Test
GOLD STANDARD
Infection No infection
TP: FP:
FN: TN:
DATA IN PAPER
GOLD STANDARD
Sepsis No infection
CORRECTION
44. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la étaient les suivantes pour les patients ayant reçu au
moins une dose d’antibiotique au cours des 24 heures précédant le prélèvement
sanguin pour la mesure de la (s’il-vous-plaît, n’écrivez rien dans la table
de contingence à droite):
Méta-analyse, livret, PCT et CRP
xxx
Test
GOLD STANDARD
Infection No infection
TP: FP:
EN: TN:
DATA IN PAPER
GOLD STANDARD
Sepsis No infection
CORRECTION
45. En vous fiant à votre lecture de l’article, les données relatives au diagnostic d’une
infection par la étaient les suivantes pour les patients n ‘ayant pas reçu
au moins une dose d’antibiotique au cours des 24 heures précédant le prélèvement
sanguin pour la mesure de la CRP (s’il-vous-plaît, n’écrivez rien dans la table de
contingence à droite):
GOLD STANDARD
Infection No infection
TP: FP:
EN: TN:
GOLD STANDARD
Sepsis No infection
Test
DATA IN PAPER CORRECTION
Méta-analyse, livret, PCT et CRP
Annex 1V Lyout of ihe tetter to the authoi
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Date
Address
Re: meta-analysis PCT and CRP
Dear Dr.:
We are performing a meta-analysis on the validity of PCI and CRP as diagnostic markers
of infection in hospitalized patients. This meta-analysis will include this paper that you
have written:
Since this meta-analysis should include your paper, we would like you to verify the
following data and to answer to the following questions:
In this study, the test evaluated was/were:
D Procalcitonin (PCT)
D C-reactive protein (CRP)
In this study, the diagnosis of infection was based on (please, check ail positive answers)
D clinical data
D radiological data
u sample of tracheal respiratory secretions
u sample of lower respiratory secretions (brush specimen, bronchoalveolar lavage,
etc)
D blood culture
D catheter tip culture
u culture of spinal fluid
D stool culture
D urine culture
D culture of skin
D abiopsy
D an autopsy
D culture for bacteria
u culture for fungi
D culture for virus
D increase of antibody titer
u serological identification of germ(s) (i.e. ELISA)
D biochemical identification of germ(s) (i.e. PCR)
Please, specify:
_______________________
D other criteria:
Please, specify:
__________
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Data onprocalcitonin (PCT)
From your paper we extracted the number of patients in each category (infection vs no
infection) according to PCT resuits (contingency table on the lefi). Please, complete the
contingency table on the right if the data is incorrect.
PCI +
Threshold
______________
_____________
_____________
_____________
ng/mL
PCI-
GOLD STANDARD
Infection No Infection
GOLD STANDARD
Infection No Infection
TP: fP:
FN: TN:
PCI +
Threshold
PCI-
TP: fP:
FN:
N=
DATA IN THE PAPER CORRECTION
xxxiv
Data on C-reactive protein (CRP)
From your paper we extracted the number of patients in each category (infection vs no
infection) according to CRP results (contingency table on the lefi). Please, complete the
contingency table on the right if the data is incorrect.
CRP+
Threshold
_____________
_____________
_____________
_____________
mg/dL
CRP
GOLD STANDARD
Infection No Infection
GOLD STANDARD
Infection No Infection
TP: FP:
FN: TN:
CRP+
Threshold
CRP
TP: fP:
fN: TN:
N=
DATA IN THE PAPER CORECTION
xxxv
Attached to this letter is a list ofpapers we found that evaluated the validation of PCI or
CRP for diagnosis of infection in hospitalized patients. If you are aware ofany other
paper or study — published or not — on the subject, please write these references or
indicate the address of the principal authors.
Please, retum this questionnaire with the label enclosed.
I thank you for your kind attention to this matter.
Sincerely,
Jacques Lacroix, M.D.
Division ofPediatric Intensive Care
Department of Pediatrics
Sainte-Justine Hospital
3175 Côte Sainte-Catherine
Montréal (Québec)
Canada H3T 1C5
Telephone (office): (514)-345-4675
FAX: (514)-345-4822
E-mail:
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